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ABSTRACT 
Lynn S. Chollet Hinton: Epidemiology of Breast Cancer among Young Black Women and the Rise in 
Young-Onset Distant Disease in the U.S. 
(Under the direction of Melissa Troester) 
 
Purpose: Rates of distant (stage IV) breast cancer have significantly increased since 1976 among 
young women <40 years. Young-onset breast cancers tend to be more aggressive with poorer 
prognosis than older-onset disease, particularly among black women. This dissertation sought to 
clarify the impact of shifting incidence by (1) characterizing the epidemiology of young black 
women’s breast cancer, and (2) investigating temporal shifts in breast cancer biology and diagnostic 
imaging use as contributors to rising young-onset distant disease. 
Methods: We examined tumor characteristics and breast cancer risk factors associated with 
premenopausal young (<40) vs. older (≥40) black women’s breast cancer in the African American 
Breast Cancer Epidemiology and Risk Consortium (2,008 cases; 5,144 controls) using unconditional 
logistic regression. Additionally, we examined longitudinal breast cancer incidence using joinpoint 
regression among young women (20-39 years) from 1992-2011 according to breast tumor 
characteristics in the Surveillance, Epidemiology, and End Results (SEER) program. Temporal 
patterns in imaging use (positron emission tomography, computed tomography, magnetic resonance 
imaging, bone scans) were examined separately among Medicare-eligible breast cancer cases using 
SEER-Medicare-linked data. 
Results: Premenopausal black women <40 years had higher frequency of poorer-prognostic tumor 
characteristics compared to older (≥40) women, including negative estrogen and progesterone 
receptor (ER/PR) status, triple-negative subtype, high grade, higher stage, and larger tumor size. 
Adiposity, family history of breast cancer, and oral contraceptive use were associated with increased 
risk for young women while breastfeeding was more strongly protective. In SEER, the frequency of 
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favorable tumor characteristics significantly increased while less favorable characteristics declined 
among young women. Imaging use dramatically increased from 1992-2011 among SEER-Medicare 
cases and was significantly associated with less favorable characteristics, including ER/PR negativity, 
high grade, and tumor size >2cm. 
Conclusions: Among premenopausal black women, young age (<40 years) was associated with more 
aggressive breast tumor biology. Modifiable risk factors including breastfeeding, adiposity, and oral 
contraceptive use may be important targets for mitigating harms of young-onset breast cancer. In 
SEER, the frequency of aggressive disease decreased while imaging use dramatically increased from 
1992-2011, suggesting that stage migration rather than shifting tumor biology has contributed to 
rising incidence of young-onset distant breast cancer. 
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CHAPTER 1: BACKGROUND 
1.1 Overview: Breast Cancer in the U.S. 
Breast cancer is the most common cancer and second leading cause of death among women 
in the United States (U.S.). Approximately 1 in 8 women are diagnosed with breast cancer during 
their lifetime, totaling nearly 300,000 new cases and 40,000 deaths each year(1, 2). In the U.S., the 
American Cancer Society recommends annual mammographic screening to all women over 40 years 
of age as a method for identifying breast cancers early, and as a result the majority of breast cancers 
are early-stage (in situ or stage I/II) rather than advanced-stage (stage III/IV) at time of diagnosis(3, 
4). As with many other cancer sites, breast cancers that are localized to breast tissue (early-stage) 
have much improved treatment options and prognoses than do regional (stage III) or distant 
metastatic (stage IV) cases that have spread to other organ systems. However, breast cancer is a 
complex and heterogeneous disease, and trends in breast cancer incidence vary by age, race, and stage 
at diagnosis. Continued advances in breast cancer epidemiology are needed to further breast cancer 
prevention efforts and reduce the burden of advanced-stage breast cancers. 
1.2 Breast cancer biologic heterogeneity 
Although breast cancer as a whole has a high burden of morbidity and mortality in the U.S., 
breast cancer is not considered to be a single disease. Rather, breast cancer is comprised of a group of 
disease subtypes with distinct molecular, morphological, and clinical features that are associated with 
diverse incidence, prognosis, and survival patterns. Based on analyses of tumor gene expression, 
breast cancers have been divided into five subtypes (or six with the inclusion of normal breast-like 
tumors), including luminal A, luminal B, basal-like, HER2 over-expressing, and the recently 
identified Claudin-low tumors(5, 6). However, in the absence of tumor genomic data, these subtypes 
are approximated via immunohistochemical tests of hormone receptors (estrogen and progesterone 
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(ER/PR) receptors and human epidermal growth factor receptor 2 (HER2)), resulting in four 
conventional subtypes: luminal A (ER positive and/or PR positive and HER2 negative), luminal B 
(ER positive and/or PR positive and HER2 positive), basal-like (negative for all three receptors), and 
HER2-enriched (ER/PR negative and HER2 positive). Subtyping newly diagnosed breast cancers by 
immunohistochemistry has become routine clinical practice, revolutionizing the treatment of breast 
cancer by tailoring therapies to target to specific tumor subtypes.  
However, tumor subtypes differ with respect to the availability of targeted therapies, 
aggressiveness, and clinical outcomes, resulting in disparities in incidence and prognosis across 
subtypes. Tumors with ER or PR positivity (luminal tumors) can be targeted with anti-estrogenic 
therapies in addition to conventional breast cancer treatments and tend to be lower grade and slower 
proliferating, resulting in favorable prognosis and improved survival compared to other subtypes(6-
10). In contrast, HER2-enriched breast cancers are associated with aggressive, higher grade, and 
faster proliferating disease, making these breast cancers more likely to recur and metastasize 
following initial treatment and leading to poor patient outcomes(11-13). However, the introduction of 
HER2-targeting adjuvant treatments has substantially improved disease-free survival rates among 
women with HER2-positive breast cancers(14-16). Only basal-like breast cancers have no targeted 
therapies; these tumors grow independently of ER, PR, and HER2 expression and can have varied 
response to chemotherapy, greatly limiting treatment options(10). Furthermore, like HER2-enriched 
cancers, basal-like breast cancers tend to be more aggressive with higher grade and highly 
proliferative disease, thereby resulting in higher rates of disease recurrence and significantly reduced 
survival(8, 10). Figure 1.1 illustrates the survival curves for each subtype prior to the availability of 
targeted treatments, demonstrating the marked variation in survival for each subtype(6).  
These biological differences across breast cancer subtypes suggest distinct etiologies, and 
epidemiologic studies have identified heterogeneity in the associations between breast cancer risk 
factors and risk of each subtype, particularly when comparing ER-positive and ER-negative disease. 
While some risk factors (e.g., family history of breast cancer, alcohol consumption, smoking history, 
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oral contraceptive use, and hormone replacement therapy use) appear to impact breast cancer risk 
similarly across all subtypes, reproductive and body size exposures are differentially associated with 
luminal (ER-positive) and basal-like (ER-negative) tumors(17, 18). Specifically, luminal breast 
cancers are associated with older age at menarche, later age at first birth, lower parity, and 
postmenopausal adiposity, while basal-like breast cancers are associated with younger age at 
menarche, younger age at first birth, higher parity, lack of breastfeeding, and pre- and 
postmenopausal adiposity(17-19). Given the disparate associations with survival between subtypes, 
differences in risk factor distributions in luminal vs. basal-like breast cancers can have substantial 
implications for breast cancer aggressiveness, prognosis, and patient outcomes. Furthermore, the 
associations between risk factors and tumor subtypes are modified by both age and race.  
1.3 Breast cancer heterogeneity by age 
Increasing age is the strongest risk factor for breast cancer, with approximately 78% of all 
new breast cancers occurring among women over 50 years of age(20). However, age is a complex 
risk factor, serving as a proxy for known and unknown age-associated exposures (e.g., genetic, 
behavioral, or environmental exposures that shift throughout the life course) that may promote cancer 
development(21). As such, many breast cancer risk factors vary with respect to age, including 
reproductive, behavioral, body size, and environmental exposures. Thus, examining age trends in 
breast cancer incidence can reveal heterogeneity in how risk factor exposure contributes to breast 
cancer risk over the life course. 
As shown in Figure 1.2, age at diagnosis is strongly associated with overall breast cancer 
incidence, and the incidence of breast cancer among young women under 40 years of age is low. 
Indeed, less than 7% of all breast cancers in the U.S. are diagnosed among women <40 years(1, 22). 
However, although breast cancer among young women <40 years is rare, it is well-established that 
young women’s breast cancer is more aggressive and proliferative than disease among older women. 
Young women tend to have a higher prevalence of basal-like breast cancers, larger and higher-grade 
primary tumors, ER and PR negativity, HER2 overexpression, p53 mutations, lymphovascular 
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invasion, and increased risk of regional and distant metastases than women diagnosed at a later 
age(22-27). Additionally, breast cancer tumors arising in young women have distinct patterns of gene 
expression compared to those occurring in older women, suggesting that breast cancers among young 
vs. older women are biologically distinct(27). The poor prognosis associated with younger-onset 
breast cancer has been shown to significantly reduce overall and relapse-free survival(22, 26-30). 
Additionally, women <40 years typically do not receive mammographic screening, and the incidence 
and survival patterns associated with older, screened populations (e.g., early-stage cancers, increased 
ER/PR-positive disease, and smaller, lower grade tumors) are not evident within this demographic. 
Indeed, the majority of breast cancers among young women are self-detected and more advanced at 
time of diagnosis(29, 31), contributing to a higher incidence of advanced-stage disease. 
Epidemiologic studies have identified differences in the distribution of breast cancer risk 
factors with respect to age at diagnosis that may contribute to etiologic differences in young- vs. 
older-onset breast cancer(32-36). However, previous studies have used inconsistent definitions of 
young age, with some studies using varying young age cutoffs (40, 45, or 50 years) and others using 
pre- vs. postmenopausal status to represent young vs. older age(17, 34, 35, 37-40). Furthermore, the 
reported associations between breast cancer risk factors and age at diagnosis have been mixed, 
yielding inconsistent conclusions regarding whether breast cancers arising in young and older women 
have distinct etiologies. 
Reproductive and body size exposures are the most established risk factors with 
heterogeneity in the effect on breast cancer risk across age. For example, risk of breast cancer has 
been shown to be temporarily elevated in the first several years following a pregnancy, after which 
parity is associated with reduced risk of breast cancer later in life(41-43). Breast cancers arising 
during or following pregnancy are known as pregnancy-associated breast cancers and are associated 
with more aggressive disease, higher likelihood of metastasis, and poor clinical outcomes(41, 42). 
The period of increased risk following pregnancy occurs among women of all ages, although the risk 
for women with later age at first birth (over age 30-35 years) is significantly higher than that for 
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women with younger age at first birth(41, 42). Because young women <40 years of age are more 
likely to have been recently parous than older women, young parous women are at increased risk of 
breast cancer while older parous women experience a protective effect(35, 42, 43). Additionally, oral 
contraceptive use has been reported to increase breast cancer risk among young women but not older 
women, a finding thought to be due to recency of oral contraceptive use among young women during 
their reproductive years(34, 35). Finally, obesity is well-known to be associated with reduced risk of 
breast cancer among young women and elevated risk among older women(44-47); however, this 
inverse relationship appears to be limited to ER/PR positive breast cancers, as obesity does appear to 
increase the risk of basal-like breast cancer among young women(17, 19).  
Breast cancer risk modification by age for other established risk factors has been less clear 
(e.g., age at menarche, age at last birth, breastfeeding history, alcohol consumption, and smoking 
history)(32, 35, 36). Because breast cancer among young women is rare, previous work has generally 
been conducted in study populations with limited representation of young women(34-36, 38), 
resulting in uncertainty about the epidemiology of young women’s breast cancer. Age differences in 
breast cancer tumor biology and aggressiveness are well-established, and further work examining the 
epidemiology of young-onset breast cancer in larger populations of young women is needed to 
identify modifiable targets for breast cancer prevention within this demographic. 
1.4 Racial differences in breast cancer incidence 
 Breast cancer incidence patterns are known to differ significantly between black and white 
U.S. women. The “black-white crossover” is a well-described phenomenon that has been observed 
when comparing breast cancer incidence by age and race. This crossover, illustrated in Figure 1.3, 
refers to the incidence shift that occurs around age 40: black women have higher incidence rates than 
white women until age 40, after which black women have lower incidence rates than white women(2, 
48, 49). However, black women tend to have more aggressive disease and higher mortality rates than 
white women at all ages(2), and these racial differences in breast cancer incidence and patient 
outcomes suggest etiologic differences by race. 
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 Indeed, numerous studies have identified differences in the presentation of breast cancers 
among black and white women that are not entirely explained by differences in cultural or 
socioeconomic factors. Black women are more likely to have higher stage disease at diagnosis as well 
as larger, higher grade tumors and an increased prevalence of ER-negative, p53 mutated, and basal-
like tumors than are white women (8, 21-23, 48-57). Furthermore, black women are less likely to 
report having a mammogram in the previous three years(53), more likely to experience treatment 
delays (particularly among young black women)(58), and less likely to receive a first treatment course 
that meets national cancer treatment standards(55), all contributing to poorer clinical outcomes and 
increased mortality among black women. Taken together, these established racial differences in breast 
cancer presentation and clinical outcomes suggest that breast cancers among black and white women 
may be biologically distinct.  
 Racial differences in breast cancer epidemiology are also important in breast cancer 
disparities. Aggressive breast cancers are more prevalent among young women <40 years, and a 
higher proportion of young women with breast cancer are black(23, 48). Indeed, black and white 
women appear to have distinct age at incidence curves (Figure 1.4), with a higher proportion of young 
cases being black and a higher proportion of older cases being white(48). Both races appear to have 
bimodal age at incidence trends with clusters of breast cancer diagnoses around 40 and 70 years of 
age, although black women tend to be diagnosed at earlier ages than white women (Figure 1.4). In 
studies comparing risk factor exposure distributions by race, black women tend to have higher obesity 
rates, reduced breastfeeding, and higher parity than white women(17, 56, 59), factors that are all 
associated with increased risk of basal-like breast cancer. Indeed, approximately 20% of the 
difference in late-stage disease between black and white women has been attributed to obesity 
alone(56), while 53% of basal-like breast cancers occurring in black women are thought to be 
preventable by reducing obesity and increasing breastfeeding among black women(17).  
 However, young black women under age 40 years are at greatest risk for aggressive breast 
cancers, and very little research has investigated whether breast cancer risk factor exposure differs 
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with respect to age among black women. Hall et al.(59) reported increased risk of breast cancer 
among younger (<50 years) black multiparous women (3 or more pregnancies) compared to older 
(≥50 years) multiparous black or white women. Mayberry et al.(60) observed that young (<40 years) 
black women with long oral contraceptive use (at least 10 years) and obesity had elevated risk 
compared to older black women with similar oral contraceptive use and obesity, while age at 
menarche under 13 years was protective against breast cancer for young but not older black women. 
Other work examining the epidemiology of young- vs. older-onset breast cancer among black women 
has been limited and reported null or imprecise effect estimates due to small sample sizes(17). 
However, these studies suggest heterogeneity in the epidemiology of breast cancer by age among 
black women, and additional work in larger study populations with sufficient representation of young 
black women is needed.  
1.5 Longitudinal incidence trends in breast cancer 
Recent studies of longitudinal breast cancer incidence trends have revealed shifts in breast 
cancer incidence over time related to age, race, and specific tumor characteristics. Overall, breast 
cancer incidence trends have varied substantially over the past several decades, largely due to 
advancements in screening and changes in exposure patterns to breast cancer risk factors (e.g., rising 
obesity rates, delayed childbearing, and decreased hormone replacement therapy use)(20). With the 
introduction of widespread mammographic screening in the late 1970s, overall breast cancer 
incidence rose dramatically in the 1980s and 1990s due to marked improvements in the detection of 
early-stage (in situ and stage I and II) disease (Figure 1.5)(3, 4). Following this surge in incidence, 
breast cancer rates began to decline in the late 1990s, a trend that has since been attributed primarily 
to decreased use of menopausal hormone therapy (MHT) following the highly publicized risks of 
MHT use reported by the Women’s Health Initiative(3, 61). However, evidence suggests that the rates 
of early-stage breast cancers have again been rising in recent years(3, 4), and the underlying reasons 
for this recent increase are unknown. In comparison, the incidence of late-stage breast cancers (stage 
III and IV) has been markedly lower since the advent of widespread mammography, and the majority 
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of breast cancers diagnosed in the U.S. are early-stage (Figure 1.5). Over the past several decades, 
late-stage breast cancer incidence has been relatively stable with a slight but significant decrease in 
the incidence of regional and distant metastatic breast cancers(3, 4).  
Because breast cancer among young women is rare, breast cancer incidence trends among 
U.S. women overall more strongly represent older women. Indeed, recent evidence suggests that 
longitudinal breast cancer incidence rates differ among young vs. older women, particularly with 
respect to stage at diagnosis. Among women <40 years of age, the incidence of localized and regional 
disease at diagnosis has been stable since 1976; however, rates of distant metastatic breast cancer 
have significantly and consistently increased since 1976 among young women(21, 62), with one study 
estimating that distant disease rates have nearly doubled within this demographic(4). As shown in 
Figure 1.6, distant disease has been increasing among young women more sharply in recent years, 
with a 3.6 percent increase in incidence each year from 2000-2009(4). Although breast cancer 
incidence is low among young women, the prognosis of metastatic breast cancer is poor (5-year 
survival is 25%)(63), and the increasing trend has inspired substantial concern. Johnson et al.(4) also 
found that distant disease significantly increased among women aged 40-54 years, albeit at a slower 
rate of 0.6% per year. In contrast, the incidence of distant disease remained stable for women 55-69 
years and decreased slightly but significantly for women aged 70-84 years at diagnosis(4). In older 
women, Anderson et al.(21) reported stable or decreasing rates of distant disease and observed a 
stage-shift from distant/regional to local disease. Thus, women of older ages appear to mirror 
incidence trends of U.S. women overall, with increasing early-stage and decreasing late-stage breast 
cancers over time, while incidence rates of distant disease are significantly increasing among young 
women at an increasing rate over time. 
Given that young black women have a higher prevalence of aggressive and late-stage breast 
cancers compared to young white and older women, increased distant disease among women <40 
years may have been influenced by incidence among young black women. While several studies have 
examined whether longitudinal breast cancer incidence trends vary by race in the U.S.(1, 2, 21, 48, 
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64, 65), research investigating incidence patterns by age among black women is limited(21, 48, 64). 
Anderson et al.(21) identified increasing rates of distant disease among both young black and white 
women from 1974-2003, though black women aged 20-29 years had the greatest increase of any 
demographic group. Later, Anderson et al.(48) reported that more white than black women were 
diagnosed at an early age from 1975 to 1995, after which black women represented a larger 
proportion of early-onset disease. Similarly, Hou et al.(64) identified that young black women had 
higher incidence rates than young white women from 2000-2009, although they did not examine how 
trends in young-onset distant disease varied by race. While these studies demonstrate racial 
differences in breast cancer incidence by age, no known studies have investigated stage-specific 
incidence trends in young black vs. white women past 2003, when rates of distant disease were 
increasing most rapidly(4). 
Several studies have examined how breast cancer incidence has varied by tumor 
characteristics over time. Evidence suggests that among U.S. women overall and among black and 
white women under age 50 years, ER positive disease has significantly increased from 1974-2010 
(combined study years)(1, 21, 64). These studies have also reported reduced incidence of ER negative 
disease overall and either reduced(1, 64) or stable(21) ER negative disease among younger black and 
white women. These trends are consistent with expectation given large representation of older 
women. However, the observed decrease in ER negative disease among younger black and white 
women suggests that more aggressive ER negative tumors may be declining; thus, the increase in 
distant disease within this demographic may be attributable to factors other than temporal shifts in ER 
status. However, trends in ER status have not been examined in conjunction with stage at diagnosis, 
and ER status may be independently associated with trends in distant disease. With regard to other 
tumor characteristics, Anderson et al.(21) investigated how tumor grade varied over time among 
young women but found that both high and low grade disease increased in parallel among young 
black and white women through 2003 with no evidence that tumors of either grade were increasing 
more rapidly. Only one known study has investigated trends in other tumor characteristics (i.e., PR 
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status and tumor size), and this study did not include young women <40 years nor consider 
differences in trends by race. Shifts in other aggressiveness markers (e.g., PR and HER2 status, tumor 
size, grade, tumor subtype, and lymph node positivity) may have contributed to the rise in distant 
disease among young women and merit further study. 
 Finally, while temporal shifts in tumor aggressiveness may have impacted longitudinal breast 
cancer incidence trends, stage migration due to advances in diagnostic imaging technology may have 
also contributed to the recent rise in distant breast cancer among young black and white women. This 
phenomenon refers to a shift in the distribution of cancer stages within a population that is unrelated 
to cancer biology. Rather, changes to the cancer staging system or the use of improved diagnostic 
techniques results in the classification of cancer patients into different stages than would previously 
have been assigned(66). Evidence from studies of lung cancer suggests that the use of new imaging 
technology (i.e., computed tomography (CT), positron emission tomography (PET), and magnetic 
resonance imaging (MRI)) identifies previously undetectable distant metastases, resulting in 
misleading stage-specific incidence and survival trends as patients are classified as stage IV rather 
than stage III without a change in the actual state of their disease(66-69). It is unknown whether stage 
migration has contributed to the rise in distant metastatic breast cancer as well. The influence of 
imaging use on breast cancer staging has not been investigated, and shifts in the clinical 
recommendations for advanced imaging over time based on breast cancer tumor characteristics may 
have impacted national trends in breast cancer incidence. Investigating whether new imaging 
technologies have contributed to stage-specific incidence trends over time will reveal whether shifting 
trends in distant disease could simply be spurious artifacts of stage migration and shed light on the 
clinical use of these technologies.  
1.6 Conclusions and study rationale 
 In summary, breast cancer is a complex disease composed of multiple distinct subtypes with 
incidence patterns that vary by age and race over time. Young black women less than 40 years of age 
are particularly at risk for aggressive, advanced-stage breast cancers with fewer treatment options, 
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worse prognosis, and decreased survival. The rate of distant disease at diagnosis has significantly 
increased among young black and white women since 1973, with the sharpest increases occurring 
since 2000. This rise in advanced-stage disease among women most at risk for poor clinical outcomes 
is concerning, and the underlying reasons for the increasing trend are unknown. These young-onset 
breast cancers appear to have a distinct etiology from older-onset breast cancers; however, studies 
investigating differences in breast cancer aggressiveness and epidemiology among young vs. older 
women have been rare and generally underpowered. Furthermore, the epidemiology of breast cancers 
arising in young black women is poorly understood. Further study investigating the role of breast 
cancer biology and stage migration on incidence trends in young black women’s breast cancer is 
needed to understand the changing burden of breast cancer incidence. 
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Figure 1.1. Overall survival for the five original gene expression-based tumor subtypes. Sorlie et 
al.(6). 
 
 
Figure 1.1 legend. ERBB2+ represents HER2+ subtype. 
  
  
13 
 
Figure 1.2. Age-specific breast cancer incidence rates in SEER, 1973-2010. 
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Figure 1.3. Age-specific incidence rates for breast cancer among white and black women in SEER, 
1975-2004. Anderson et al.(48). 
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Figure 1.4. Age distributions at diagnosis by race in SEER, 1975-2004. Anderson et al.(48). 
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Figure 1.5. Incidence of stage-specific breast cancer in the U.S. in SEER, 1976-2008. Bleyer et al.(3). 
 
 
 
 
  
  
17 
 
Figure 1.6. Annual incidence of distant breast cancer among young women (25-39 years) from 1976-
2009 by SEER registry and era. Johnson et al.(4). 
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CHAPTER 2: SPECIFIC AI MS 
Breast cancer is the most commonly diagnosed cancer and the second leading cause of death 
among women in the U.S.(2). Significant advancements in breast cancer epidemiology, screening, 
diagnosis, and treatment have resulted in improved breast cancer detection and survival over time(2, 
20, 61, 70, 71). However, recent epidemiologic evidence suggests that rates of distant metastatic 
(stage IV) breast cancer have increased since 1976, especially among young women <40 years of 
age(4, 21, 62). These observed trends are particularly pronounced among young (<40 years) black 
women, among whom distant disease rates have increased more sharply compared to those for white 
women(4, 21). Although breast cancer incidence is low within this age group relative to older women, 
these findings are of concern given that breast cancer among young black women is associated with 
more aggressive and proliferative breast cancer subtypes, poorer prognosis, fewer therapy options, 
and reduced survival compared to diagnoses at a later age(17, 22, 28). The factors contributing to this 
rise in distant metastatic breast cancer are unknown, and an investigation into the epidemiology of 
young-onset breast cancer among black women is needed to identify targets for mitigating or 
preventing advanced-stage disease. Aggressive breast cancers are more prevalent among young black 
women(8, 17, 50), and we hypothesize that temporal shifts in breast cancer aggressiveness may have 
contributed to the recent rise in distant disease within this demographic. 
Aim 1. To identify tumor characteristics and risk factors for young-onset (<40 years) breast 
cancer among premenopausal black women in the AMBER Consortium. To describe the 
characteristics of breast cancer among young black women, we will identify (a) tumor characteristics 
(ER, PR, and HER2 positivity; subtype; grade; stage; tumor size; and lymph node status) and (b) 
breast cancer risk factors (BMI, parity, breastfeeding history, oral contraceptive use, etc.) that are 
differentially associated with breast cancer according to age at diagnosis (<40 vs. ≥40 years).  
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Hypothesis: Young age at diagnosis (<40 years) will be associated with more aggressive tumors 
(ER/PR negativity, HER2 positivity, high grade, advanced stage, large primary tumor size, and 
lymph node positivity) and with distinct breast cancer risk factor distributions (especially in 
relation to reproductive exposures). 
Aim 2. To describe the biological and imaging patterns associated with distant disease among 
black and white women.  
Aim 2a. To examine how tumor biological characteristics contribute to temporal trends in distant 
disease, we will use joinpoint regression(72) and SEER 1992-2011 data to estimate the association 
between tumor characteristics (ER/PR status, tumor grade, and primary tumor size) and stage-specific 
incidence rates among young women <40 years, stratified by race (black vs. white).  
Hypothesis: Young cases with distant stage disease will have increasing markers for aggressive 
disease over time, supporting the “biological shift” hypothesis(17, 37, 73-75). 
Aim 2b. Shifts in imaging technology use may have inflated trends in the rates of distant disease due 
to improved ability to detect asymptomatic metastases at diagnosis(66-69). To evaluate whether stage 
migration due to increased imaging technology use (CT, PET, MRI, and/or bone scans) over time has 
contributed to rising rates of distant breast cancer among young women, joinpoint regression and 
SEER-Medicare linked data (1992-2011) will be used to describe how imaging use has changed over 
time and whether imaging use patterns differ by breast cancer tumor characteristics (ER/PR status, 
tumor grade, and primary tumor size) among older (≥65 years) U.S. women. 
Hypothesis: Imaging use will have increased over time and will vary by tumor characteristics, 
with the greatest increases in use occurring among women with aggressive tumor characteristics, 
supporting the “stage migration” hypothesis. 
The proposed study will investigate whether shifts in breast cancer aggressiveness contributed to the 
rise in distant metastatic breast cancer among young women. Characterizing the biology, 
epidemiology, and diagnostic imaging characteristics of aggressive, advanced-stage breast cancers 
over time will yield targets for intervention and clarify the public health impact of these trends. 
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CHAPTER 3: METHODS 
3.1 Study Design Overview 
 This dissertation involved two overarching aims and analysis strategies to characterize 
young-onset breast cancer among black women and examine temporal trends in the incidence of 
distant stage disease. Figure 3.1 illustrates a conceptual model of these aims. In Aim 1, case-case and 
case-control analyses were used to identify tumor characteristics and breast cancer risk factors that 
were differentially associated with young- vs. older-onset breast cancer among black women in the 
African American Breast Cancer Epidemiology and Risk (AMBER) Consortium. Second, Aim 2 used 
joinpoint regression to examine how temporal trends in breast tumor characteristics (Aim 2a) and 
imaging use (Aim 2b) have contributed to national trends in stage-specific breast cancer incidence 
rates among young (<40 years) U.S. women in the Surveillance, Epidemiology, and End Results 
(SEER) 13 program from 1992-2011. Using SEER-Medicare linked data from 1992-2011, Aim 2b 
also characterized whether imaging use varied by stage at diagnosis and breast tumor characteristics. 
3.2 Study Populations 
 To address the aims of this dissertation, data from three study populations were used: the 
African American Breast Cancer Epidemiology and Risk (AMBER) Consortium, the Surveillance, 
Epidemiology, and End Results (SEER) 13 program from 1992-2011, and the SEER-Medicare linked 
program from 1992-2011. 
3.2.1 AMBER Consortium  
 The African American Breast Cancer Epidemiology and Risk (AMBER) Consortium is a 
collaboration between four epidemiologic studies of breast cancer among black women: the Carolina 
Breast Cancer Study (CBCS), the Black Women’s Health Study (BWHS), the Women’s Circle of 
Health Study (WCHS), and the Multi-Ethnic Cohort (MEC) Study(76). These four studies combined 
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breast cancer risk factor exposure data (genetic, biologic, reproductive, and lifestyle) for black 
women with and without breast cancer, as well as molecular and genetic tumor characteristics for 
breast cancer cases. Taken together, these parent studies represent a pooled study population of over 
10,000 U.S. black women with data extending from 1993-2014, making the AMBER Consortium one 
of the largest and most extensive breast cancer studies of black women in the U.S.  
 Carolina Breast Cancer Study (CBCS). The CBCS is a population-based, case-control study 
involving 24-44 counties of central and eastern North Carolina. Women of all races were eligible for 
inclusion if they were 20-74 years of age at the time of diagnosis (cases) or study recruitment 
(controls). As described previously(17, 58, 77, 78), the CBCS collected extensive clinical, molecular, 
and epidemiologic data for in situ and invasive breast cancer cases diagnosed from 1993-1996 (Phase 
I), 1996-2001 (Phase II), and 2008-2013 (Phase III). Cases were identified through rapid case 
ascertainment by the North Carolina Central Cancer Registry; controls were recruited (for Phases I 
and II only) through North Carolina Department of Motor Vehicles records and Health Care 
Financing Administration records for Medicare enrollment. Phase III recruited only invasive breast 
cancer patients and expanded the case catchment area to 44 North Carolina counties. Randomized 
recruitment was used to oversample younger (<50 years) and African American cases as well as to 
frequency-match controls to cases by age (<50 vs. ≥50 years) and self-reported race (African 
American vs. non-African American)(77). The CBCS contributed 701 premenopausal African 
American breast cancer cases from Phases I-III and 298 controls from Phases I-II to this analysis. 
 Black Women’s Health Study (BWHS). The BWHS is a prospective cohort study of U.S. 
black women’s health from 17 mainland states; the regional distribution of participants is 28% 
Northeast, 30% South, 23% Midwest, and 19% West(79). Participants were recruited in 1995 through 
mail questionnaires sent to Essence Magazine subscribers, members of the Black National Education 
Association and Black Nurses’ Association, and friends and relatives of respondents(79). A total of 
59,000 black women aged 21 to 69 were enrolled following completion of a baseline questionnaire 
assessing demographic information, medical and family history, and biologic, reproductive, and 
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lifestyle exposures(79). Since 1997, follow-up questionnaires have been mailed to all participants 
biennially to update exposure history and record incident disease and mortality data, with a follow-up 
success rate of 80%(80). For participants reporting breast cancer diagnoses, clinical information 
relating to the diagnosis and tumor pathology was abstracted from medical records or obtained from 
local cancer registries(80). The BWHS contributed 738 premenopausal cases and 4,281 controls to 
this analysis. 
 Women’s Circle of Health Study (WCHS). The WCHS is a case-control study of breast cancer 
involving black and white women living in New York and New Jersey. Initially, the WCHS was a 
hospital-based case-control study recruiting English-speaking white and black women aged 20-75 
years from New York boroughs (Manhattan, Bronx, Brooklyn, and Queens) beginning in January 
2002(81). Women with histologically-confirmed incident breast cancers were defined as cases and 
women with no previous diagnosis of cancer (other than non-melanoma skin cancer) were defined as 
controls. However, in March 2006 the study later expanded to New Jersey and became population-
based, with cases identified from the New Jersey Cancer Registry and controls recruited by random 
digit dialing or through church and health fair events occurring in communities from which cases 
were recruited(81). Controls were frequency-matched to cases by race and 5-year age groups. The 
WCHS is ongoing, with current enrollment limited to black women living in 10 New Jersey counties; 
New York recruitment was discontinued in December 2008(81). All cases and controls are 
interviewed in their homes by study personnel, and all participants provide biologic, lifestyle, 
reproductive, and medical history information. The WCHS contributed 569 premenopausal black 
cases and 565 controls to this analysis.  
 Multi-Ethnic Cohort (MEC). The MEC is a prospective cohort study conducted in Hawaii and 
Southern California examining risk factors associated with cancer in an ethnically diverse study 
population of white, black, Asian American, Japanese American, Latino, and Native Hawaiian men 
and women. Over 215,000 English- and Spanish-speaking participants (16,594 black women) aged 45 
to 69 years were recruited from 1993-1996 through a mailed baseline questionnaire assessing 
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demographic, medical, reproductive, lifestyle, and family histories. Participants completed a five-year 
follow-up questionnaire in 1999-2001 and repeated the baseline questionnaire in 2003-2008 to update 
exposure data. Incident breast cancer cases were identified by linkage with the Hawaii Tumor 
Registry and Los Angeles County Cancer Surveillance Program, and mortality information is 
obtained through linkage with the California and Hawaii state death certificate files as well as the 
National Death Index. While the MEC contributes approximately 1,053 incident breast cancer cases 
to AMBER, the MEC was excluded from the present analysis, as their exclusion criteria limited 
participants to ≥45 years of age. 
 Pooled AMBER data. The final AMBER study population includes black premenopausal 
breast cancer cases and controls from the CBCS, BWHS, and WCHS parent studies. The two case-
control studies (CBCS and WCHS) contribute all enrolled premenopausal cases and controls to 
AMBER, while the BWHS provided nested case-control data comprised of all premenopausal 
incident breast cancer cases and up to four controls for each case. The BWHS controls were randomly 
selected and matched to cases by year of birth and by completion of the same follow-up questionnaire 
prior to the case’s diagnosis(76). Data collection in AMBER is ongoing, with additional cases and 
controls added to the pooled study population as follow-up continues in the ongoing parent studies 
and as breast tumor tissue samples are processed for genetic and molecular data. 
 The AMBER study population for Aim 1 of this dissertation included all premenopausal 
black cases diagnosed with invasive breast cancer and matched controls from the CBCS (701 cases, 
298 controls), WCHS (569 cases, 565 controls), and BWHS (738 cases, 4,281 controls), for a total 
study population of 7,152 women (2,008 cases, 5,144 controls). All postmenopausal women (defined 
based on self-reported cessation of menstruation, bilateral oophorectomy, or ovary irradiation), and 
women with unknown menopausal status were excluded to estimate age effects independent of 
menopausal status. Each study and the AMBER Consortium collaboration were approved by 
Institutional Review Boards at participating institutions, and all participants gave written informed 
consent. 
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3.2.2 SEER 1992-2011 
 The SEER research program, led by the National Cancer Institute (NCI), has collected cancer 
incidence and survival data from a collection of U.S. cancer registries since 1973. The original SEER 
program involved 9 cancer registries and has since expanded to 18 registries throughout the U.S. 
(Table 3.1). The SEER expansions were completed to diversify the study population and increase 
heterogeneity by race/ethnicity, thus improving the external validity of the SEER program over 
time(82). SEER currently covers approximately 28% of the total U.S. population, and the registries 
participating in SEER are carefully selected to ensure that included cancer cases are representative of 
the general U.S. population in terms of education status and poverty level and that minority races and 
ethnicities are adequately represented(82, 83). In general, the SEER program is highly generalizable 
in terms of education, poverty level, and race/ethnicity, although SEER tends to have slightly higher 
proportions of urban and foreign-born persons than the total U.S. population(82).  
 Because the SEER program is a collection of cancer registries, all incident cancer cases 
diagnosed in participating areas are reported to SEER by local hospitals, clinicians, and pathology 
laboratories. SEER requires that each registry report all cases within two years of diagnosis, after 
which cases are followed for demographic, clinical, and mortality data(82). This selection process 
results in a complete population of all cancer cases within participating geographical areas that 
together are representative of the general U.S. population. In total, the SEER program captures 
incidence and survival data for over 7.7 million cancer cases throughout an almost 40-year study 
period, making the SEER program the largest and most comprehensive population-based cancer 
epidemiologic data source in the country.  
 This dissertation involved SEER data collected from 1992-2011, and thus this subpopulation 
included breast cancer cases in the SEER 13 program, as these registries have continuously collected 
data throughout the study period (Table 3.1). Because SEER registries did not routinely report tumor 
characteristics prior to 1990 and 4 racially-diverse SEER registries were added in 1992(83), the 
subpopulation was limited to all breast cancer cases with diagnosis dates beginning in 1992 in order 
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to ensure consistent reporting of tumor characteristics variables and to maximize racial heterogeneity. 
The inclusion criteria for this study were 1) U.S.-residing women 20-39 years of age, and 2) a first 
primary breast cancer diagnosis (ICD-O-3 cancer sites C50.0-50.9) between January 1, 1992 and 
December 31, 2011 that was reported to SEER. Women with a personal history of cancer prior to the 
first primary breast cancer diagnosis or a primary breast cancer diagnosed at time of death or autopsy 
were excluded. The final SEER 13 study population (1992-2011) included 30,407 incident breast 
cancer cases among young women (<40 years). 
3.2.3 SEER-Medicare 1992-2011 
 The SEER-Medicare program links the cancer incidence data within SEER to healthcare 
utilization claims data available in Medicare. This data linkage has existed since 1991 and includes all 
SEER cancer cases diagnosed after 1991 who were eligible for Medicare (≥65 years of age or 
diagnosed with end-stage renal disease, amyotrophic lateral sclerosis, or medical disability)(84). The 
SEER-Medicare linkage is updated every 2-3 years by the NCI, SEER, and CMS through a 
collaborative process in which eligible cancer cases are matched by personal identifiers (name, social 
security number, sex, and date of birth) to Medicare claims(85, 86). An estimated 93% of all eligible 
SEER cancer cases diagnosed since 1991 have been successfully linked to Medicare claims(86). 
Although the SEER-Medicare population has been found to have lower poverty rates, higher 
proportion of minority races, greater urban vs. rural living, and decreased cancer mortality than the 
general U.S. elderly population(85), the magnitude of these differences is small and the external 
validity of these data to the elderly U.S. population remains very high considering that 97% of elderly 
Americans are enrolled in Medicare(85).  
 The current study utilized SEER-Medicare data for breast cancer cases diagnosed from 1992-
2011. Inclusion criteria were: 1) U.S.-residing women ≥65 years of age, 2) a first primary breast 
cancer diagnosis (ICD-O-3 cancer sites C50.0-50.9) between January 1, 1992 and December 31, 2011 
that was reported to SEER, and 3) Medicare enrollment at time of diagnosis (parts A/B coverage and 
no health maintenance organization (HMO) enrollment). Women with a personal history of cancer 
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prior to the first primary breast cancer diagnosis or a primary breast cancer diagnosed at time of death 
or autopsy were excluded. The final subpopulation included 142,051 breast cancer cases ≥65 years 
from the SEER 13 registries that are linked to Medicare claims data. 
The purpose of including SEER-Medicare data in addition to the full SEER program was to 
describe the use of diagnostic imaging technology over time in a national U.S. cancer population 
during a period of dramatic change in the use of imaging for breast cancer staging (1992-2011). 
Medicare data include the type of imaging technology used, diagnostic codes, and date of service, and 
the linkage to SEER enables an investigation into imaging trends over time within a national U.S. 
cancer population. While we were unable to directly assess temporal trends in imaging use among 
young women within this population, this aim sought to identify imaging patterns in a national 
population of breast cancer cases and evaluate how clinical recommendations for advanced imaging 
vary by disease characteristics in the U.S. 
3.3 Data Collection 
3.3.1 Aim 1: AMBER Consortium 
Breast cancer risk factors. The AMBER Consortium’s breast cancer risk factor data were 
collected through either self-reported mailed questionnaires (BWHS) or home interviews conducted 
by study nurses (CBCS and WCHS). Although the AMBER Consortium involved harmonizing risk 
factor data obtained from different study populations, the demographic, reproductive, and medical 
history data relevant to this proposed study were collected using very similar questions and coding 
schemes across all contributing studies. Participants were asked questions regarding their medical and 
family histories as well as biologic, anthropomorphic, reproductive, and lifestyle exposures. For 
CBCS and WCHS, interviewers also measured body weight, height, and waist and hip circumferences 
during home interviews; for the BWHS, these measures were self-reported on questionnaires by study 
participants. Questionnaire and interview data from each study were then harmonized by the AMBER 
Biostatistics and Data Management core within AMBER to create a central database with consistent 
exposure definitions across studies. Breast cancer risk factors were categorized as: age at menarche 
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(<13, ≥13 years), parity (nulliparous, 1-2, ≥3 births), age at first live birth (<25, ≥25 years), age at last 
live birth (<30, ≥30 years), time since last birth (<10, ≥10 years), lifetime duration of breastfeeding 
(never, <3 months, ≥3 months), oral contraceptive use (never, ever), duration (never/<1 year, 1-4 
years, 5-9 years, ≥10 years) and recency (never, <10 years, ≥10 years), and first-degree family history 
of breast cancer (no, yes). Body mass index (BMI) was defined as body weight/height (kg/m2) using 
categories from the National Heart, Lung, and Blood Institute (<25 normal/underweight, 25.0-29.9 
overweight, and ≥30 obese)(87). Waist-to-hip ratio (WHR) was calculated as the ratio of waist/hip 
circumference (cm) and categorized in tertiles as <0.77, 0.77-0.83, and ≥0.84, consistent with 
previous work(88). 
 Tumor characteristics. Tumor characteristic data were obtained from patient medical records 
or from tumor tissue blocks collected at time of surgery for all breast cancer cases. The three studies 
included in this analysis (CBCS, BWHS, and WCHS) contributed breast tumor tissue when available 
to two core research facilities (the Translational Pathology Lab (TPL) at the University of North 
Carolina at Chapel Hill (UNC) for the CBCS and the Roswell Park Cancer Institute for the WCHS 
and BWHS) where tissue microarrays (TMAs) were constructed for available tumor specimens. 
Immunohistochemistry (IHC) assays were conducted on all TMAs at UNC’s TPL to define 
expression of estrogen and progesterone receptors (ER/PR) and human epidermal growth factor 
receptor 2 (HER2)(89). Positive expression was defined as ≥1% staining for ER and PR, and ≥10% 
staining at the 3+ level for HER2 consistent with previous work(89). Breast cancer subtype was 
defined as four groups based on positivity of three IHC markers: luminal A (ER+ or PR+, HER2-), 
luminal B (ER+ or PR+, HER2+), HER2+/ER- (ER-, PR-, HER2+), and basal-like (ER-, PR-, HER2-
). For cases with missing IHC-based tumor characteristics, ER, PR, HER2, and subtype data were 
defined from medical records; cases with both IHC-based and clinical hormone receptor data showed 
high agreement for the two measures (κ statistic range=0.68-0.76, concordance range=88-91%). 
Tumor grade was centrally reviewed by a study pathologist for 44% of cases, with grade data 
obtained from medical records for remaining cases (κ statistic=0.95, concordance=96% for both grade 
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measures). Other tumor characteristics (including stage (1-4), lymph node status (positive vs. 
negative), and estimated tumor size (<2, 2-4.9, ≥5cm)) were acquired from medical records. 
3.3.2 Aim 2: SEER and SEER-Medicare  
Tumor characteristics. The SEER program records several markers of breast tumor 
aggressiveness (ER/PR status, tumor grade, primary tumor size, and stage) for all breast cancer cases. 
These tumor characteristics are obtained from pathology reports or medical records, and the accuracy 
of these markers is verified to be at least 98% through random medical record reviews(82, 85). 
ER/PR status was recorded as positive, borderline, negative, and unknown. Given that clinical 
standards defining hormone receptor positivity changed over the study period, varying from 1-10%, 
we combined positive and borderline cases to approximate more recent guidelines of 1% positivity 
recommended by the American Society of Clinical Oncology/College of American Pathologists(90). 
Tumor grade was defined at time of diagnosis by a pathologist as low (well-differentiated), moderate 
(moderately-differentiated), high (poorly-differentiated) and undifferentiated (anaplastic). 
Undifferentiated tumors (defined as grade 4) were uncommon (approximately 3% of cases) and were 
excluded from all grade analyses. Primary tumor size was defined as the single largest tumor 
dimension prior to any neoadjuvant cancer therapy and dichotomized as ≤2cm vs. >2cm.  
Stage at diagnosis was defined using SEER’s historic stage A coding of four summary stage 
categories, as this coding has remained consistent in SEER throughout the study period. While breast 
cancer staging systems have been refined and improved over time, the SEER and SEER-Medicare 
programs utilize an extent-of-disease reporting scheme that has been in place since 1988 to create 
SEER summary stages that have remained consistent over time(82). Specifically, stage at diagnosis 
was defined as in situ (noninvasive cancer), local (invasive cancer confined to the breast), regional 
(tumor extension to breast skin, chest wall, and/or regional lymph nodes), and distant (metastasis to 
non-breast tissues).  
 Diagnostic imaging technology: SEER-Medicare includes data regarding the use of 
diagnostic imaging technologies while enrolled in Medicare for all eligible cancer cases. In this 
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dissertation, diagnostic imaging technologies referred to all imaging technologies that have been used 
from 1992-2011 to identify whether a breast cancer has metastasized at the time of diagnosis (i.e., 
CT, PET, MRI, and/or bone scans). In this study, imaging use was defined as having at least one 
imaging claim in a given calendar year. Use of these technologies was defined using relevant 
Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology (CPT) 
imaging codes corresponding to these technologies from 1992-2011 (Table 3.2). Breast cancer cases 
were considered “imaged” if at least one of these four imaging scans was received between 2 months 
prior and 4 months following the primary diagnosis date within SEER. This exposure window was 
selected to identify imaging used incidentally prior to cancer diagnosis and to allow sufficient time 
for complete disease staging post-diagnosis. Breast cancer is not typically diagnosed and staged using 
a single diagnostic test: the disease is generally diagnosed via biopsy of a detected lesion in the 
breast(91-94), and final staging occurs following surgical removal of the lesion, lymph node 
biopsy/dissection, and/or diagnostic imaging. Time since initial diagnosis to complete staging has 
been reported to range from less than 1 month to over 3 months(57, 95-97), and similar studies 
examining the use of imaging technology at time of cancer diagnosis have previously utilized this 6-
month timeframe to assess technology use throughout the diagnostic time period(68, 98). 
3.4 Analysis methods 
3.4.1. Aim 1. To identify tumor characteristics and risk factors for young-onset (<40 years) 
breast cancer among premenopausal black women in the AMBER Consortium.  
Case-case and case-control analyses were conducted to identify differences in the 
associations between tumor characteristics and epidemiologic risk factors and breast cancer by age at 
diagnosis (<40 vs. ≥40 years) among premenopausal black women (age range 22-59 years). Case-case 
analyses of tumor characteristics associated with young- vs. older-onset disease included all cases 
(N=2,008), while case-control analyses of risk factors included all cases and controls except cases 
from Phase III of the CBCS (total N=6,736), as no matched controls were available for this study 
phase. Case-control analyses examined risk factor associations for breast cancer among young and 
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older women overall and further stratified by ER status among young women, in which ER-positive 
and ER-negative cases were compared separately to all controls. Unconditional logistic regression 
models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) to assess 
differences in tumor characteristics and breast cancer risk factors associated with breast cancer by age 
at diagnosis for all analyses. In case-control analyses, effect measure modification by age was 
evaluated using likelihood ratio tests in which the estimated log-likelihood of the adjusted model was 
compared to that of the same model including a multiplicative interaction term for age and the 
corresponding risk factor. Statistically significant modification was assessed using an α-level of 0.1.  
Heterogeneity in risk factor associations by ER status among young women was assessed by 
comparing case-case odds ratios (ORs), with ER status defined as the outcome and each risk factor as 
the explanatory variable. These case-case ORs represent the ratio of case-control ORs for risk factors 
associated with ER-positive vs. ER-negative disease, and statistical significance was defined using an 
α-level of 0.05. Additionally, we conducted sensitivity analyses to examine whether patterns of tumor 
characteristics and risk factors associated with young- vs. older-onset disease were impacted by the 
cutpoint used to define young age (40, 45, and 50 years). All models controlled for study, diagnosis 
year, geographic region, and education status to account for differences between studies. Case-control 
models additionally adjusted for other risk factors that were identified a priori via directed acyclic 
graphs as potential confounders of each risk factor association. Models for age at first live birth, age 
at last live birth, time since last birth, and lifetime breastfeeding duration were restricted to parous 
women. Statistical significance was defined at an α-level of 0.05. All analyses were performed using 
SAS software, version 9.4 (SAS Institute, Inc., Cary, North Carolina). 
3.4.2 Aim 2. To describe the biological and imaging patterns associated with distant disease 
among black women. 
3.4.2.1 Aim 2a. To examine how tumor biological characteristics contribute to temporal trends in 
distant disease among young women <40 years in the SEER 13 program from 1992-2011.  
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To assess trends in distant breast cancer among young women <40 years of age during our 
20-year study period, we used SEER*Stat software (version 8.3.2(99)) to calculate annual stage-
specific breast cancer incidence rates from 1992-2011 in the SEER 13 program, adjusted for age 
using the 2000 U.S. standard population. Incidence rates were calculated for young women overall 
and stratified by black and white race to identify whether temporal trends in stage at diagnosis vary 
according to race.  
Both Aims 2a and 2b used joinpoint regression(72) (version 4.4.0.0(100)) to model 
longitudinal SEER and SEER-Medicare data. Joinpoint regression, also known as piecewise 
regression, is an established statistical method for modeling cancer incidence rates over time, and the 
model estimation process has been described in detail previously(72). To summarize, logarithm-
transformed incidence rates or proportions are modeled over time by fitting a series of linear trends 
that pivot at “joinpoints” corresponding to points in time at which the slope of the cancer incidence 
trend significantly changes. The total number of joinpoints is determined through a permutation 
process: the regression model first fits the simplest model with 0 joinpoints (meaning a single linear 
trend over the entire time period), after which the number of joinpoint terms is serially increased to 
test whether including additional joinpoints significantly improves model fit, up to a maximum of 3 
joinpoints for the current study, based on time period length. Following this forward estimation 
process, the final model estimates the best-fit series of linear trends with slope changes at statistically 
significant joinpoints (see Figure 3.2 for example). The slope parameters estimated for each linear 
segment are known as annual percentage change (APC) estimates, and p-values for each APC are 
calculated via Monte Carlo permutation methods. Weighted average APCs (AAPCs) are then 
calculated to generate a single percent change estimate for the time period and to quantitatively 
compare trends across analyses(101). 
 To address Aim 2a and examine the “biological shift” hypothesis, we calculated annual stage-
specific incidence rates and annual incidence rates according to ER/PR status, tumor grade, and 
primary tumor size, overall and among cases with distant stage disease at diagnosis. All incidence 
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rates were adjusted for age using the 2000 U.S. standard population, and analyses of tumor 
characteristics were restricted to invasive breast cancer cases (N=26,870). We then used joinpoint 
regression to calculate AAPCs estimating temporal trends in stage and breast tumor characteristics 
from 1992-2011 among young women overall and according to race (black vs. white). Substantial 
missing data has been documented for tumor characteristics reported to SEER, particularly for ER 
and PR status (approximately 25% in 1992), which may bias longitudinal studies of incidence 
rates(102, 103). To clarify whether data are missing at random across characteristics, we 
characterized patients with missing data by estimating descriptive statistics with chi-square 
significance testing for cases with and without missing data, and used joinpoint regression to examine 
whether the distribution of breast cancer cases (as measured by percent of cases) varied over time 
with respect to each tumor characteristic. 
3.4.2.2 Aim 2b. To evaluate whether stage migration due to increased imaging technology use (CT, 
PET, MRI, and/or bone scans) over time has contributed to rising rates of distant breast cancer among 
young women <40 years. 
 To investigate the “stage migration” hypothesis, annual rates of imaging use were calculated 
overall and by imaging type (CT, PET, MRI, and bone scans) among older breast cancer cases in 
SEER-Medicare from 1992-2011. Joinpoint regression was used as described above to estimate 
AAPCs for all longitudinal trends. Sensitivity analyses were conducted excluding elderly women 
(over age 75) as well as varying the 6-month imaging window to 3 months post-diagnosis; however, 
these exclusions did not substantially impact results beyond reductions in study power and therefore 
were not employed in final analyses. Unconditional logistic regression was used to estimate age-
adjusted odds ratios (ORs) and 95% confidence intervals (CIs) to assess the associations between 
imaging use and tumor biological characteristics. Logistic regression analyses were performed using 
SAS software, version 9.4 (SAS Institute, Inc., Cary, North Carolina). Statistical significance for all 
analyses was defined at an α-level of 0.05.  
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 The concerns described above (3.4.2.1 Aim 2a) for missing breast tumor characteristics data 
in SEER also apply to the SEER-Medicare data. Unlike Aim 2a, Aim 2b did not involve the 
estimation of temporal trends in tumor characteristics with substantial time-varying missing data, and 
thus complete-case analyses were conducted to evaluate the association between imaging use and 
breast tumor characteristics. Additionally, the use of administrative claims data carried concerns 
about the accuracy of procedure codes (such as the CPT and HCPCS codes used in this study) that are 
reported in claims data. It is possible that procedure code errors resulted in misclassification of the 
imaging use exposure and thus created bias in the proposed statistical analyses. While no known 
validation studies have been conducted to evaluate the sensitivity and specificity of the relevant 
imaging technology codes, similar studies examining imaging technology use in cancer populations 
have previously utilized these same procedure codes with success(68, 95, 104). Additionally, these 
imaging technologies are expensive healthcare procedures that are more likely to be reported 
accurately to ensure appropriate provider reimbursement compared to other lower cost procedures, 
suggesting that imaging use data are likely to be well-represented in healthcare utilization data 
sources such as the SEER-Medicare program.  
3.5 Strengths and Limitations 
 To our knowledge, this study is the first to investigate whether temporal shifts in breast 
cancer biology have contributed to the recent increase in distant metastatic breast cancer among 
young women. This work characterized the epidemiology of breast cancer among young black 
women by examining how a comprehensive list of tumor characteristics and breast cancer risk factors 
vary with respect to age at diagnosis. Previous studies of young-onset breast cancer among black 
women have been limited by small sample sizes, and by using AMBER data this study extended 
previous work using one of the largest available breast cancer epidemiology data sources for black 
women in the U.S.  
Additionally, the SEER program is the most extensive and comprehensive population-based 
cancer epidemiologic data source in the U.S., and the use of this very large study population enabled 
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an examination of longitudinal incidence trends among young women <40 years, stratified by race 
and tumor characteristics. The use of SEER data also allowed for an investigation into shifts in tumor 
biology as an underlying reason for the increased rates of distant disease among young women within 
the data source originally used to identify those incidence trends. Furthermore, the SEER and SEER-
Medicare data spanned from 1992 to 2011, a time period that encompasses the period of greatest 
change in distant disease incidence among young women and a period of rapid advancements in 
imaging technologies. The use of SEER-Medicare data allowed an exploration into the roles of 
shifting imaging use and stage migration in stage-specific breast cancer incidence trends among 
elderly U.S. women and evaluated how imaging use recommendations may vary clinically by tumor 
characteristics. Additionally, while missing tumor characteristic data was of concern for the early 
years of the SEER program, verified multiple imputation methods and careful evaluation of 
missingness within the SEER data were employed to address the missing data for ER/PR status and 
any other predictors.  
Ultimately, this dissertation thoroughly characterized the epidemiology of young-onset breast 
cancer among black women and examined breast cancer biology and imaging use as potential 
underlying reasons for temporal shifts in stage-specific breast cancer incidence rates among young 
women <40 years in the U.S. This work sought to identify potentially modifiable targets for public 
health intervention against young-onset breast cancers among black women and clarify the public 
health impact of the rising incidence of distant disease among young women. 
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Figure 3.1. Summary of aims and hypotheses. 
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Figure 3.2. Sample joinpoint regression model.  
 
 
Figure 3.2 legend. Boxes mark two joinpoints resulting in three annual percent change (APC) 
estimates. 
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Table 3.1. Timeline of SEER program expansions, 1973-2011.(82) 
 
SEER program Data years Included cancer registries 
SEER 9 1973–2011 
Atlanta, Connecticut, Detroit, Hawaii, Iowa, New 
Mexico, San Francisco-Oakland, Seattle-Puget Sound, 
Utah 
SEER 11 1992–2011 SEER 9, Los Angeles, San Jose-Monterey 
SEER 13 1992–2011 SEER 11, Rural Georgia, Alaska Native Tumor Registry 
SEER 17 2000–2011 
SEER 13, Greater California, Kentucky, Louisiana, New 
Jersey 
SEER 18 2000–2011 SEER 17, Greater Georgia 
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Table 3.2. Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding 
System (HCPCS) codes defining diagnostic imaging technology use. 
 
Imaging Technology Category CPT/HCPCS Codes 
CT Brain/Head 70450-70492 
 Breast/Chest 72125-72133 
 Abdomen 71250-71270, 72192-72194, 74150-74170, 74176-74178 
 Bone 73200-73202, 73700-73702 
 Body 76380, 76497 
   
PET Body 
78608, 78609, 78810-78816, G0125, G0126, G0165, G0210-
G0228, G0231-G0235, G0252-G0254, G0296, G0330, G0331 
   
MRI Brain/Head 70336, 70540, 70542, 70543, 70551-70553, 70557-70559 
 Breast/Chest 
71550-71552, 75552, 75553, 75557, 75561, 76093, 76094, 
77058, 77059, C8903-C8908 
 Abdomen 72195-72197, 74181-74183 
 Bone 
72141, 72142, 72146-72149, 72156-72158, 73218-73223, 
73718-73723 
 Body 76498 
   
Bone scan  
(nuclear medicine) 
Bone/Body 
76400, 78800-78804, 78102-78104, 78300-78320, 78399, 
78999 
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 CHAPTER 4: BIOLOGY AND ETIOLOGY OF YOUNG-ONSET BREAST CANCERS 
AMONG PREMENOPAUSAL BLACK WOMEN: RESULTS FROM THE AMBER 
CONSORTIUM 
 
4.1 Introduction 
 Black women have increased rates of breast cancer with greater prevalence of advanced 
stage, larger size, higher grade, hormone receptor negative, and basal-like disease compared to white 
women(8, 21, 22, 48-53, 105). Similar tumor biology is also evident in young-onset (<40 years) 
breast cancers, which are more common among black women(22, 23, 26, 27). Differences in risk 
factor profiles for young and older women may reflect distinct etiologies for breast cancers arising in 
young and black women. Risk factors such as parity, age at first birth, oral contraceptive use, and 
obesity have been shown to differentially affect the risk of breast cancer according to age at 
diagnosis(17, 19, 34, 35, 43, 45-47, 88). These same risk factors are also differentially associated with 
hormone receptor positive and negative disease(17-19, 106, 107), which may confound observed age-
related patterns. However, population-based studies examining whether risk factor associations vary 
by age at diagnosis among black women are rare and have been hampered by small sample sizes, 
overall and by age(17, 59, 60). Furthermore, previous studies of young women’s breast cancer have 
used inconsistent definitions of young age, defining young with varying age cutpoints or confounding 
age and menopausal status(17, 34-36, 38, 59, 60, 108, 109), complicating comparisons across studies. 
 The present study investigated risk factors for young black women’s breast cancer in the 
African American Breast Cancer Epidemiology and Risk (AMBER) Consortium, a large 
collaboration of breast cancer studies among black women with extensive clinical, molecular, and 
epidemiologic data. We restricted our analysis to premenopausal women, as previous work has 
suggested that age and menopausal status may have independent roles in young women’s breast 
cancer(36, 88). Our objectives were two-fold: first, to characterize the biology of breast cancers 
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diagnosed among young and older premenopausal black women in the AMBER Consortium, and 
second, to identify epidemiologic risk factors associated with premenopausal young- vs. older-onset 
breast cancers overall and by estrogen receptor (ER) status. We hypothesized that more aggressive 
breast tumor characteristics and distinct patterns of breast cancer risk factors would be associated 
with young-onset breast cancers (<40 years), and ER status would modify observed risk factor 
associations by age at diagnosis. 
4.2 Methods 
4.2.1 Study population 
 The African American Breast Cancer Epidemiology and Risk (AMBER) Consortium is a 
collaboration of four of the largest epidemiologic studies of breast cancer among black women(76). 
Included are two case-control studies, the Carolina Breast Cancer Study (CBCS) (17, 58, 77) and 
Women’s Circle of Health Study (WCHS)(81), as well as two prospective cohort studies, the Black 
Women’s Health Study (BWHS)(79) and the Multiethnic Cohort Study (MEC)(110). The AMBER 
Consortium and participating studies have been described in detail previously(76). Briefly, the CBCS 
recruited breast cancer cases and controls aged 20-74 years across 24-44 North Carolina counties in 
three phases (Phase 1: 1993-1996, Phase II: 1996-2001, and Phase III (cases only): 2008-2013). The 
WCHS recruited cases and controls aged 20-75 years in New York (2002-2008) and New Jersey 
(2006-present). The BWHS enrolled participants aged 21-69 years from 17 continental states in 1995 
with biennial follow-up to record changes to exposure history, incident disease, and mortality. The 
MEC recruited participants aged 45-69 years in Hawaii and southern California from 1993-1996, with 
5-year follow-up questionnaires. Cohort studies (BWHS and MEC) provided nested case-control data 
to the Consortium comprised of all incident breast cancer cases and up to four matched controls for 
each case(76).  
The present study included premenopausal black cases diagnosed with invasive breast cancer 
and matched premenopausal controls from the CBCS (701 cases, 298 controls), WCHS (569 cases, 
565 controls), and BWHS (738 cases, 4,281 controls), for a total study population of 7,152 women 
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(2,008 cases, 5,144 controls). All postmenopausal women (defined based on self-reported cessation of 
menstruation, bilateral oophorectomy, or ovary irradiation), and women with unknown menopausal 
status were excluded to estimate age effects independent of menopausal status. Additionally, the 
MEC was excluded from this analysis due to their exclusion criteria limiting to women ≥45 years of 
age. Each study and the AMBER Consortium collaboration were approved by Institutional Review 
Boards at participating institutions, and all participants gave written informed consent. 
4.2.2 Data collection 
The collection of tumor characteristic and risk factor exposure data in the AMBER 
Consortium has been described previously(76, 89). Briefly, each study contributed paraffin-embedded 
breast tumor tissue for all cases to two core research facilities (the Translational Pathology Lab (TPL) 
at the University of North Carolina at Chapel Hill (UNC) for the CBCS and the Roswell Park Cancer 
Institute for the WCHS and BWHS) where tissue microarrays (TMAs) were constructed for available 
tumor specimens. Immunohistochemistry (IHC) assays were conducted on all TMAs at UNC’s TPL 
to define expression of estrogen and progesterone receptors (ER/PR) and human epidermal growth 
factor receptor 2 (HER2)(89). Positive expression was defined as ≥1% staining for ER and PR, and 
≥10% staining at the 3+ level for HER2 consistent with previous work(89). Breast cancer subtype 
was defined as four groups based on positivity of three IHC markers: luminal A (ER+ or PR+, HER2-
), luminal B (ER+ or PR+, HER2+), HER2+/ER- (ER-, PR-, HER2+), and triple-negative (ER-, PR-, 
HER2-). For cases with missing IHC-based tumor characteristics, ER, PR, HER2, and subtype data 
were defined from medical records; cases with both IHC-based and clinical hormone receptor data 
showed high agreement for the two measures (κ statistic range=0.68-0.76, concordance range=88-
91%). Tumor grade was centrally reviewed by a study pathologist for 44% of cases, with grade data 
obtained from medical records for remaining cases (κ statistic=0.95, concordance=96% for both grade 
measures). Other tumor characteristics (including stage (1-4), lymph node status (positive vs. 
negative), and estimated tumor size (<2, 2-4.9, ≥5cm)) were acquired from medical records. 
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Risk factor exposure data for cases and controls were obtained via in-home interviews by 
study staff (CBCS and WCHS) or mailed questionnaire (BWHS), as described previously(76). 
Participants were asked questions regarding their medical and family histories as well as biologic, 
anthropomorphic, reproductive, and lifestyle exposures. For CBCS and WCHS, interviewers also 
measured body weight, height, and waist and hip circumferences during home interviews; for the 
BWHS, these measures were self-reported on questionnaires by study participants. Questionnaire and 
interview data from each study were then harmonized by the AMBER Biostatistics and Data 
Management core within AMBER to create a central database with consistent exposure definitions 
across studies. Breast cancer risk factors were categorized as: age at menarche (<13, ≥13 years), 
parity (nulliparous, 1-2, ≥3 live births), age at first live birth (<25, ≥25 years), age at last live birth 
(<30, ≥30 years), time since last live birth (<10, ≥10 years), lifetime duration of breastfeeding (never, 
<3 months, ≥3 months), oral contraceptive use (never, ever), duration (never/<1 year, 1-4 years, 5-9 
years, ≥10 years) and recency (never, <10 years, ≥10 years), and first-degree family history of breast 
cancer (no, yes). Body mass index (BMI) was defined as body weight/height (kg/m2) using categories 
from the National Heart, Lung, and Blood Institute (<25 normal/underweight, 25.0-29.9 overweight, 
and ≥30 obese)(87). Waist-to-hip ratio (WHR) was calculated as the ratio of waist/hip circumference 
(cm) and categorized in tertiles as <0.77, 0.77-0.83, and ≥0.84, consistent with previous work(88). 
4.2.3 Statistical analysis 
 Case-case and case-control analyses were conducted to identify differences in the 
associations between tumor characteristics and epidemiologic risk factors and breast cancer by age at 
diagnosis (<40 vs. ≥40 years) among premenopausal black women (age range 22-59 years). Case-case 
analyses of tumor characteristics associated with young- vs. older-onset disease included all cases 
(N=2,008), while case-control analyses of risk factors included all cases and controls except cases 
from Phase III of the CBCS (total N=6,736), as no matched controls were available for this study 
phase. Case-control analyses examined risk factor associations for breast cancer among young and 
older women overall and further stratified by ER status among young women, in which ER-positive 
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and ER-negative cases were compared separately to all controls. Unconditional logistic regression 
models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) to assess 
differences in tumor characteristics and breast cancer risk factors associated with breast cancer by age 
at diagnosis for all analyses. In case-control analyses, effect measure modification by age was 
evaluated using likelihood ratio tests in which the estimated log-likelihood of the adjusted model was 
compared to that of the same model including a multiplicative interaction term for age and the 
corresponding risk factor. Statistically significant modification was assessed using an α-level of 0.1. 
Heterogeneity in risk factor associations by ER status among young women was assessed by 
comparing case-case odds ratios (ORs), with ER status defined as the outcome and each risk factor as 
the explanatory variable. These case-case ORs represent the ratio of case-control ORs for risk factors 
associated with ER-positive vs. ER-negative disease, and statistical significance was defined using an 
α-level of 0.05. Additionally, we conducted sensitivity analyses to examine whether patterns of tumor 
characteristics and risk factors associated with young- vs. older-onset disease were impacted by the 
cutpoint used to define young age (40, 45, and 50 years). All models controlled for study, diagnosis 
year, geographic region, and education status to account for differences between studies. Case-control 
models additionally adjusted for other risk factors that were identified a priori via directed acyclic 
graphs as potential confounders of each risk factor association. Models for age at first live birth, age 
at last live birth, time since last birth, and lifetime breastfeeding duration were restricted to parous 
women. Statistical significance was defined at an α-level of 0.05. All analyses were performed using 
SAS software, version 9.4 (SAS Institute, Inc., Cary, North Carolina). 
4.3 Results 
4.3.1 Breast tumor biology varies by age at diagnosis among black women (case-case analyses)  
Among premenopausal black women, young age (<40 years) at breast cancer diagnosis was 
associated with poorer-prognostic tumor characteristics compared to older age at diagnosis (≥40 
years) (Table 4.1). Young women were significantly more likely to have higher stage and triple-
negative tumors. While not significant, both luminal B and HER2-enriched tumors were associated 
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with younger age at diagnosis. Young-onset breast cancers were also significantly more likely to be 
ER and PR negative, with markedly higher grade and larger tumor size. No age associations were 
observed for lymph node positivity. 
4.3.2 Age modifies breast cancer risk factor associations among black women (case-control 
analyses) 
 To examine whether breast cancers arising among young and older premenopausal black 
women are etiologically distinct, we estimated case-control ORs for risk factor associations among 
premenopausal women stratified by age (Table 4.2). Age at diagnosis most strongly modified 
associations with first-degree family history of breast cancer, with a three-fold increase in risk among 
young women that was attenuated among older women(interaction p=0.005). Likelihood ratio tests 
also showed significant age modification for associations with waist-to-hip ratio (p=0.06) and 
breastfeeding duration (p=0.1). Higher WHR was more strongly associated with young- compared to 
older-onset breast cancer, while breastfeeding, regardless of duration, had a reduced OR for young- 
but not older-onset disease. ORs for BMI were not significantly modified by age, though obese BMI 
(≥30 kg/m2) was more strongly associated with a reduced association among young women. 
Associations with parity were not modified by age, though the association with nulliparity was 
slightly reduced among young women and parity ≥3 births appeared to reduce the odds of disease 
among older women. Later age at first birth was associated with older-onset but not younger-onset 
breast cancer, while longer time since last birth appeared to reduce odds of breast cancer for older 
women. Oral contraceptive use showed similar patterns of association across age groups, with ever 
and more recent use as well as longer use duration associated with an increased OR among young and 
older women (p for interaction=0.3 (duration), 0.4 (recency); results not shown). Later age at 
menarche was not associated with young-onset breast cancer but showed a significantly reduced OR 
for older-onset breast cancer. In summary, we observed substantial differences in risk factor patterns 
by age among premenopausal black women, with the strongest differences for family history, body 
size, and reproductive exposures. 
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 Given the difference in tumor characteristics observed between young and older-onset breast 
cancer in black women, we examined whether breast cancer biology modified the etiologic patterns 
we observed, specifically among young women. While some analyses generated ORs that were 
imprecise, ORs stratified by ER status showed little evidence for differences in etiology according to 
ER (Table 4.3). Increased odds of young-onset breast cancer associated with higher WHR was limited 
to ER-negative disease (OR=1.64, 95% CI=0.98, 2.75), conversely, higher BMI was more strongly 
associated with reduced ER-positive disease (OR=0.61, 95% CI=0.38, 0.98). Additionally, family 
history of breast cancer was positively associated with young-onset disease regardless of ER status, 
though the association was stronger for ER-negative disease. However, no statistically significant 
differences by ER status were observed for these or any other risk factor associations that we 
examined, suggesting that etiologic associations for young-onset breast cancer are not strongly 
modified by disease subtype. 
4.3.3 Age-dependent risk factor associations are most pronounced with age 40 cutpoint 
 To examine whether our findings were sensitive to the cutpoint used to define young age, we 
repeated our analyses of tumor characteristics and risk factors associated with young-onset disease 
using older cutpoints of 45 and 50 years. We observed the strongest age-related heterogeneity when 
comparing the youngest women (<40) to women at least 40 years of age. Figure 4.1 shows ORs and 
95% CI for risk of young-onset breast cancer defined as <40, <45, and <50 in our cohort for the three 
risk factors showing the strongest heterogeneity by age: breastfeeding history (ever/never), waist-to-
hip ratio (highest/lowest tertile), and family history of breast cancer (yes/no). For all three factors, the 
associations for young-onset breast cancer were attenuated when defining young women as <45 or 
<50 at diagnosis. 
4.4 Discussion 
Using data from one of the largest and most comprehensive study of breast cancer biology 
and epidemiology among black women to date, the AMBER Consortium, we observed substantial 
differences in tumor characteristics and some evidence for etiologic heterogeneity of premenopausal 
  
46 
 
young- and older-onset breast cancers. The etiologic associations that vary by age appear not to be 
driven by differences in ER status, since few associations among young women were modified by ER 
status. Furthermore, age-dependent heterogeneity of risk factor associations with breast cancer were 
greatest when comparing the youngest women (<40) to older (≥40) premenopausal women. 
The age-related patterns of tumor characteristics we observed are consistent with previous 
findings(8, 21-23, 27, 48-53, 57, 88, 105), and our work supports the growing hypothesis that breast 
cancers diagnosed among young women <40 years are biologically distinct from those diagnosed in 
older women. It is well-established that black women are more likely to be diagnosed with breast 
cancer under 40 years of age compared with white women(22, 23, 26, 27), highlighting the 
importance of identifying prevention strategies for young women’s breast cancer, particularly for 
black women.   
Some risk factors for young-onset breast tumors are potentially modifiable. In our study, 
breastfeeding had a reduced OR for breast cancer in young women while higher WHR was associated 
with an increased odds of young-onset disease. Both risk factors showed the strongest associations 
among ER-negative tumors. In contrast, higher BMI showed an inverse association with young-onset 
disease that was strongest among ER-positive cancers, consistent with previous work(17, 19, 44-47). 
The observed differences between BMI and WHR underscore these factors as distinct measures of 
body size and suggest that abdominal adiposity, as represented by WHR, is an important factor 
contributing to young-onset disease(111-113). Few studies have examined etiologic differences 
according to age and breast cancer subtype in populations of black women. Millikan et al.(17) and 
Bertrand et al.(108) also reported that a lack of breastfeeding and higher WHR were significantly 
positively associated with young-onset and triple-negative (or ER-negative) breast cancers among 
black women in the CBCS and BWHS, respectively. Other studies in predominately white 
populations have observed similar associations(36, 88, 109), suggesting that interventions to improve 
breastfeeding rates and reduce abdominal adiposity may benefit young women of all races. Given that 
black women tend to breastfeed at lower rates and for shorter durations than white women(114) and 
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are more likely to have ER-negative disease, breastfeeding-related interventions may be particularly 
relevant for reducing risk of young-onset disease among black women. Additionally, oral 
contraceptive use ≥5 years was associated with significantly increased ORs regardless of age, with a 
stronger association among young women that did not vary according to ER status. Others have 
shown similarly increased risk with longer and more recent oral contraceptive use for young and AA 
women(35, 60, 115-117), highlighting that reduced oral contraceptive use may mitigate breast cancer 
risk within this demographic. 
Several exposures associated with young women’s breast cancer are not targetable for 
prevention. Family history of breast cancer showed the greatest heterogeneity according to age in our 
study, with a markedly higher OR among young women and a moderately elevated OR for older 
women. Family history often serves as a surrogate for genetic susceptibility for breast cancer, and 
other work has shown that women diagnosed with breast cancer at an early age have a greater 
frequency of genetic mutations related to tumorigenesis(118, 119). However, an individual’s family 
history is variable over time and changes with age; older women are more likely to have a positive 
family history than young women given that breast cancer risk increases with age. Thus, the 
attenuated risk associations that we observed among older women may be explained by a stronger 
contribution of environment (relative to germline genetics) in family history of older women. This 
also underscores that a positive family history in a young woman is a strong marker of 
familial/genetic risk. 
Reproductive exposures have most consistently shown differential patterns with breast cancer 
risk by age, as young women are more proximal to reproductive years than older women. In contrast 
to other studies, we did not observe the expected dual risk associations for parity, in which higher 
parity is associated with increased risk among young women but reduced risk for older women(41-
43). We observed suggestions of this relationship in that nulliparity was associated a slightly reduced 
risk of breast cancer among young women, though no associations with parity were statistically 
significant. However, other associations between reproductive factors and breast cancer were 
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consistent with previous work, showing younger age at first live birth and longer time since last birth 
as protective for older-onset but not young-onset breast cancer (17, 36, 88, 106, 107).  
Prior epidemiologic studies of young women’s breast cancer have used inconsistent cutpoints 
to classify young women, ranging from 35-50 years of age(17, 34-36, 38, 59, 60, 88, 108, 109). Many 
studies have also included limited representation of young women, as women <40 years of age 
represent less than 7% of all breast cancers diagnosed in the United States(1). As such, conclusions 
regarding whether young- and older-onset breast cancers have distinct etiologies have been mixed, 
and different studies have yielded varied directions and magnitudes of associations for many risk 
factors. However, reproductive (particularly parity, breastfeeding history, and age at first birth) and 
body size exposures have consistently shown the strongest differences in patterns of association for 
young and older women. We identified that varying the age cutpoint in our study population from 40 
to 50 years resulted in attenuated effect estimates with increased age for many risk factor 
associations. Additionally, dichotomizing our cohort at age 40 enabled a comparison of younger and 
older premenopausal women, as we previously showed that age and menopausal status are best 
considered as separate factors in studies of young women’s breast cancer(88). Taken together, our 
findings suggest that age-dependent heterogeneity in risk factor associations are most pronounced 
when classifying young women as <40 years. 
Our results should be interpreted in light of some limitations. Differences in breast cancer 
screening rates and/or adherence between young and older black women may have influenced some 
tumor characteristics among younger women, although screening data were unavailable in the 
Consortium. Breast cancers detected via screening tend to have more favorable tumor characteristics 
than self- or clinically-detected tumors(3, 31). However, interval cancers, or those diagnosed between 
regular screening intervals, are more likely to be aggressive and may be present regardless of 
screening(120). While screening differences may contribute to differences in observed tumor 
characteristics, screening is unlikely to have influenced the etiologic associations we described by age 
and ER status.  
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4.5 Conclusions 
 In summary, we found strong evidence that breast cancers diagnosed among young black 
women have tumor characteristics suggestive of poorer prognosis, underscoring the need for greater 
understanding of the etiology of young-onset disease. In the largest epidemiologic study of young 
black women’s breast cancer to date, our findings suggest that potentially modifiable risk factors, 
such as breastfeeding and adiposity, are associated with young-onset breast cancer, in addition to 
other non-modifiable factors such as family and reproductive history. 
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Table 4.1. Case-case ORs of tumor characteristics by age among premenopausal cases in the AMBER 
Consortium (N=2,008). 
 
 ≥40 years (ref) <40 years  
Tumor characteristic N (%) N (%) OR (95% CI)a 
Mean age (±SD) 46.2 (±4.3) 34.7 (±3.8)  
Stage    
Stage I 450 (35.8) 116 (24.9) 1.0 
Stage II 572 (45.5) 264 (56.8) 1.81 (1.34, 2.45) 
Stage III/IV 234 (18.6) 85 (18.3) 1.32 (0.90, 1.94) 
Missing 219 68  
Subtype (IHC/clinically 
defined) 
   
Luminal A 492 (51.4) 157 (43.5) 1.0 
Luminal B 150 (15.7) 49 (13.6) 1.37 (0.86, 2.17) 
HER2 65 (6.8) 29 (8.3) 1.35 (0.77, 2.37) 
Triple-negative 250 (26.1) 126 (34.9) 1.56 (1.09, 2.21) 
Missing 518 172  
ER status    
Positive 768 (62.1) 227 (52.1) 1.0 
Negative 469 (37.9) 209 (47.9) 1.35 (1.03, 1.77) 
Missing 238 97  
PR status    
Positive 699 (56.8) 199 (46.2) 1.0 
Negative 531 (43.2) 232 (53.8) 1.57 (1.20, 2.06) 
Missing 245 102  
HER2 status    
Negative 752 (77.5) 286 (78.1) 1.0 
Positive 218 (22.5) 80 (21.9) 1.15 (0.81, 1.65) 
Missing 505 167  
Histologic grade    
Low 144 (12.7) 33 (8.4) 1.0 
Moderate 373 (33.0) 117 (29.8) 2.00 (1.11, 3.62) 
High 613 (54.2) 243 (61.8) 2.17 (1.23, 3.85) 
Missing 345 140  
Node status    
Negative 486 (53.8) 175 (51.2) 1.0 
Positive 418 (46.2) 167 (48.8) 1.13 (0.87, 1.47) 
Missing 571 191  
Tumor size    
<2 cm 477 (40.2) 131 (30.6) 1.0 
2-4.9 cm 487 (41.0) 206 (48.1) 1.70 (1.28, 2.26) 
≥5 cm 223 (18.8) 91 (21.3) 1.31 (0.83, 2.07) 
Missing 288 105  
aAdjusted for study site, index year, geographic region, and education status. 
bMissing data due to ongoing data collection. 
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Table 4.2. Case-control ORs of breast cancer risk factors by age among premenopausal women in the AMBER Consortium (N=6,736). 
 <40 years (N=1,775) 
 
≥40 years (N=4,961) 
 
Test for heterogeneity 
Risk factor Controls N (%) Cases N (%) OR (95% CI)a  Controls N (%) Cases N (%) OR (95% CI)a  Χ2, df (p)b 
BMI (kg/m2)          
<25.0 466 (35.0) 149 (35.1) 1.0  955 (25.4) 283 (24.6) 1.0  0.41, 2 (0.8) 
25-29.9 368 (27.7) 119 (28.1) 0.92 (0.66, 1.28)  1,172 (31.2) 376 (32.7) 0.99 (0.81, 1.21)   
≥30.0 497 (37.3) 156 (36.8) 0.71 (0.51, 0.98)  1,628 (43.4) 491 (42.7) 0.91 (0.75, 1.10)   
Trend test   p=0.0005    p=0.2   
Missing 16 4   42 14    
WHR          
<0.77 441 (37.5) 104 (26.3) 1.0  1,166 (34.3) 1,166 (34.3) 1.0  5.70, 2 (0.06) 
0.77-0.83 341 (29.0) 128 (32.4) 1.14 (0.81, 1.59)  952 (28.0) 952 (28.0) 1.02 (0.83, 1.25)   
≥0.84 394 (33.5) 163 (41.3) 1.46 (1.04, 2.05)  1,285 (37.8) 1,285 (37.8) 1.11 (0.91, 1.35)   
Trend test   p=0.003    p=0.9   
Missing 171 33   394 77    
Age at menarche          
<13 years 803 (59.8) 251 (58.6) 1.0  2,038 (53.9) 654 (56.4) 1.0  1.19, 1 (0.3) 
≥13 years 540 (40.2) 177 (41.4) 0.97 (0.76, 1.24)  1,746 (46.1) 506 (43.6) 0.85 (0.74, 0.98)   
Missing 4 0   13 4    
Parity          
Nulliparous 516 (38.3) 111 (26.9) 0.90 (0.71, 1.14)  872 (23.0) 222 (19.1) 0.91 (0.75, 1.12)  3.04, 2 (0.2) 
1-2 births 644 (47.8) 224 (52.3) 1.0  2,081 (54.8) 654 (56.2) 1.0   
≥3 births 187 (13.9) 93 (21.7) 1.06 (0.87, 1.29)  844 (22.2) 288 (24.7) 0.88 (0.73, 1.06)   
Age at first live birthc          
<25 years 481 (59.0) 202 (63.9) 1.0  1,633 (56.9) 547 (58.8) 1.0  1.23, 1 (0.3) 
≥25 years 334 (41.0) 114 (36.1) 1.03 (0.74, 1.43)  1,238 (43.1) 383 (41.2) 1.18 (0.99, 1.41)   
Missing 16 0   54 12    
Time since last birthc          
<10 years 515 (63.6) 202 (64.1) 1.0  521 (18.3) 183 (19.7) 1.0  1.23, 1 (0.3) 
≥10 years 295 (36.4) 113 (35.9) 1.14 (0.82, 1.57)  2,323 (81.7) 744 (80.3) 0.86 (0.69, 1.07)   
Missing 21 2   81 15    
Breastfeeding durationc          
Parous, never 388 (47.7) 177 (56.2) 1.0  1,444 (50.3) 491 (52.7) 1.0  4.04, 2 (0.1) 
<3 months 114 (14.0) 30 (9.5) 0.70 (0.43, 1.16)  315 (11.0) 96 (10.3) 1.08 (0.82, 1.42)   
≥3 months 312 (38.3) 108 (34.3) 0.83 (0.58, 1.17)  1,111 (38.7) 344 (37.0) 0.94 (0.78, 1.13)   
Missing 17 2   55 11    
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Oral contraceptive use 
Never 177 (13.2) 74 (17.3) 1.0  539 (14.2) 232 (20.0) 1.0  0.13, 1 (0.7) 
Ever 1,167 (86.8) 354 (82.7) 1.22 (0.86, 1.72)  3,254 (85.8) 929 (80.0) 1.18 (0.97, 1.44)   
Missing 3 0   4 3    
Family history of breast 
cancer 
   
 
  
   
No 1,276 (94.7) 363 (84.8) 1.0  3,472 (91.4) 996 (85.6) 1.0  7.7, 1 (0.005) 
Yes 71 (5.3) 65 (15.2) 3.10 (2.08, 4.63)  325 (8.6) 168 (14.4) 1.57 (1.26, 1.94)   
aAdjusted for age, study site, index year, geographic location, education level, and confounders, by model. BMI: WHR, parity; WHR: BMI, 
parity; parity: age at first live birth; age at last live birth: parity, age at first birth; time since last birth: parity, age at first live birth, age at last 
live birth; breastfeeding duration: BMI, parity, age at first live birth, age at last live birth; oral contraceptive use: parity, age at first live birth, 
age at last live birth.  
bLikelihood ratio tests assessed age-related heterogeneity in risk factor associations by comparing the estimated log-likelihood of adjusted 
models to that of the adjusted model including a multiplicative interaction term for age and the corresponding risk factor (e.g., BMI*age). 
Statistically significant heterogeneity by age was defined with α=0.1. 
cAmong parous women. 
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Table 4.3. Case-control ORs of breast cancer risk factors by ER status among young (<40 years) premenopausal women in the AMBER 
Consortium (N=1,678). 
 Controls  ER+  ER-   
Risk factor N (%)  N (%) OR (95% CI)a  N (%) OR (95% CI)a  p for heterogeneityb 
BMI (kg/m2)          
<25.0 466 (35.0)  62 (38.3) 1.0  52 (31.0) 1.0   
25-29.9 368 (27.6)  41 (25.3) 0.80 (0.49, 1.29)  49 (20.2) 0.92 (0.56, 1.49)  0.6 
≥30.0 497 (37.3)  59 (36.4) 0.61 (0.38, 0.98)  67 (39.9) 0.87 (0.54, 1.40)  0.2 
Trend test    p = 0.0003   p = 0.3   
Missing 16  0   1    
WHR          
<0.77 441 (37.5)  41 (27.0) 1.0  38 (23.6) 1.0   
0.77-0.83 341 (29.0)  48 (31.6) 0.94 (0.57, 1.55)  62 (38.5) 1.56 (0.95, 2.55)  0.1 
≥0.84 394 (33.5)  63 (41.4) 1.15 (0.70, 1.89)  61 (37.9) 1.64 (0.98, 2.75)  0.3 
Missing 171     8    
Age at menarche          
<13 years 803 (59.8)  90 (55.6) 1.0  102 (60.4) 1.0   
≥13 years 540 (40.2)  72 (44.4) 1.08 (0.76, 1.55)  67 (39.6) 0.86 (0.60, 1.24)  0.1 
Missing 4  0   0    
Parity          
Nulliparous 516 (38.3)  42 (25.9) 0.93 (0.56, 1.54)  38 (22.5) 0.79 (0.47, 1.32)  0.7 
1-2 births 644 (47.8)  85 (52.5) 1.0  90 (53.3) 1.0   
≥3 births 187 (13.9)  35 (21.6) 0.84 (0.50 1.40)  41 (24.3) 1.04 (0.64, 1.71)  0.9 
Breastfeeding durationc          
Parous, never 388 (47.7)  59 (49.6) 1.0  79 (60.8) 1.0   
<3 month 114 (14.0)  11 (9.2) 0.84 (0.40, 1.80)  10 (7.7) 0.55 (0.25, 1.19)  0.5 
≥3 months 312 (38.3)  49 (41.2) 1.14 (0.68, 1.92)  41 (31.5) 0.88 (0.53, 1.48)  0.7 
Missing 17  1   1    
Oral contraceptive use          
Never 177 (13.2)  30 (18.5) 1.0  26 (15.4) 1.0   
Ever 1,167 (86.8)  132 (81.5) 1.47 (0.90, 2.40)  143 (84.6) 1.41 (0.84, 2.37)  1.0 
Missing 3  0   0    
Family history of breast 
cancer 
 
 
  
  
 
  
No 1,276 (94.7)  140 (86.4) 1.0  141 (83.4) 1.0   
Yes 71 (5.3)  22 (13.6) 2.63 (1.47, 4.70)  28 (16.6) 3.32 (1.92, 5.75)  0.4 
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aAdjusted for age, study site, index year, geographic location, education level, and confounders, by model. BMI: WHR, parity; WHR: BMI, 
parity; parity: age at first live birth; age at last live birth: parity, age at first birth; time since last birth: parity, age at first live birth, age at last 
live birth; breastfeeding duration: BMI, parity, age at first live birth, age at last live birth; oral contraceptive use: parity, age at first live birth, 
age at last live birth. 
bStatistically significant heterogeneity by age was defined with α=0.05. 
cAmong parous women. 
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Figure 4.1. Impact of age cutpoints on risk factor analyses. 
 
 
   
  
 
Figure 4.1 legend. Case-control ORs for associations between family history of breast cancer (yes/no; panel A), waist-to-hip ratio 
(highest/lowest tertile; panel B), and breastfeeding history (ever/never; panel C) and premenopausal young-onset breast cancer. Cutpoints 
defining “young” varied at <40, <45, or <50 years of age. Error bars represent 95% CIs.  
B. A. C. 
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CHAPTER 5: INCREASED DISTANT STAGE BREAST CANCER AMONG YOUNG 
WOMEN OVER TIME: ETIOLOGY OR TECHNOLOGY? 
 
5.1 Introduction 
 Recent epidemiologic studies have reported a rise in the incidence of distant metastatic (stage 
IV) breast cancer among young women <40 years of age in the United States(4, 21). One study 
conducted using data from the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and 
End Results (SEER) program estimated that rates of distant disease nearly doubled among young 
women from 1976-2009, with the sharpest increases in incidence occurring since 2000(4). Given the 
poor prognosis associated with distant disease, with a five-year survival rate of only 25%(63), this 
finding has prompted concern regarding possible causes for the increasing trend. Furthermore, it is 
well-established that young women less than 40 years have a higher prevalence of aggressive breast 
cancers compared to older women, including hormone receptor negative, high grade, and larger 
tumors(22-27, 36, 88). The potential impacts of rising distant disease on the burden of breast cancer 
in this at-risk demographic are unclear, underscoring a need for longitudinal studies investigating the 
underlying reasons for shifting incidence among young women. 
 One hypothesis for the rise in young-onset distant disease suggests a shift to more aggressive 
breast cancers over time. Breast cancers with poorer prognostic tumor features are faster to 
metastasize, and a greater representation of aggressive breast cancers among young women could 
contribute to increasing distant disease in young women. However, recent work conducted in SEER 
suggests that more favorable tumor characteristics (e.g., estrogen receptor (ER) positivity, low grade, 
and smaller tumor size) have increased over time among women overall, while the incidence of more 
aggressive tumor features has potentially declined(21, 64, 121). However, few studies have examined 
patterns among young women less than 40 years. Furthermore, the presence of substantial missing 
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data for some tumor characteristics in SEER has complicated the interpretation of longitudinal 
biological trends(102, 103). 
 As an alternative to the hypothesized biological shifts, stage migration may have contributed 
to increases in distant disease. Advances in diagnostic imaging technology may have led to increasing 
rates of distant breast cancer at diagnosis among young women. For example, studies of lung cancer 
showed that increased use of imaging technologies (e.g., positron emission tomography (PET), 
computed tomography (CT), and magnetic resonance imaging (MRI) technologies) identified 
previously undetectable distant metastases. It would be misleading to interpret stage-specific 
incidence trends over time as evidence of an etiologic or biological shift, as technology drives 
changing stage without an underlying change to the actual state of disease(66-69). Studies 
considering the impact of stage migration on breast cancer incidence patterns have been rare and 
yielded inconsistent results(4, 122), and the lack of longitudinal administrative healthcare claims data 
for population-based cancer studies has hampered studies of imaging use patterns.  
 The present study aimed to evaluate both breast cancer biology and stage migration as factors 
underlying recent temporal patterns for distant disease in young women (<40 years of age). Using 
data from the NCI’s SEER program, we assessed stage-specific incidence patterns and temporal 
trends in tumor biological factors associated with young-onset, distant breast cancer from 1992-2011. 
Additionally, we characterized the extent of missing data over this 20-year time period and explored 
the impact of missingness on the interpretation of longitudinal incidence trends. To assess changes in 
diagnostic patterns over the same interval, we used data from the SEER-Medicare linked program to 
evaluate patterns in the use of imaging technologies associated with breast cancer staging (i.e., PET, 
CT, MRI, and nuclear medicine bone scans). We hypothesized that these data sources could help to 
identify the most plausible causes of temporal shifts, including both breast tumor biology and stage 
migration. 
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5.2 Methods 
5.2.1 Study populations 
 Our study included female breast cancer cases diagnosed from 1992-2011 in both the 
National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) 13 
program(123) and the SEER-Medicare linked database(86). The SEER 13 program comprises cancer 
registries in Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, 
Seattle-Puget Sound, Utah, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native 
Tumor Registry that have been active since 1992, together representing approximately 15% of the 
U.S. population. The SEER-Medicare program links SEER cancer incidence data for Medicare-
eligible cancer cases to healthcare utilization claims data available in Medicare, including those for 
diagnostic imaging technology use, through a collaboration between the NCI and the Centers for 
Medicare and Medicaid Services. We selected the 20-year study period (1992-2011) based on the 
initiation of the SEER-Medicare program in 1991 and the addition of four racially-diverse SEER 
registries in 1992 (Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Tumor 
Registry) to form the SEER 13 program.  
Women residing in the U.S. women aged 20-39 years (SEER) or 65-108 years (SEER-
Medicare) were eligible for inclusion in our study if they had a first primary breast cancer diagnosis 
(ICD-O-3 cancer sites C50.0-50.9) between January 1, 1992 and December 31, 2011 that was 
reported to a SEER 13 cancer registry. Women with a personal history of cancer prior to the first 
primary breast cancer diagnosis or a primary breast cancer diagnosed at time of death or autopsy were 
excluded. To identify imaging use associated with a breast cancer diagnosis, we additionally required 
continuous fee-for-service Medicare Parts A and B enrollment and no health maintenance 
organization enrollment (to minimize incomplete claims data) for the two months prior and four 
months following the month of cancer diagnosis for SEER-Medicare cases. Our final study 
populations included 30,407 young women <40 years of age within the SEER program and 142,051 
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women ≥65 years of age in the SEER-Medicare program. This study was approved by the University 
of North Carolina (UNC) School of Medicine Institutional Review Board. 
5.2.2 Data collection 
 The collection of tumor characteristic data in SEER has been described previously(82, 85). 
Briefly, stage at diagnosis, estrogen and progesterone receptor (ER/PR) status, tumor grade, and 
primary tumor size data were collected from pathology reports or medical records. Stage at diagnosis 
was defined using SEER’s historic stage A coding of four summary stage categories, as this coding 
has remained consistent in SEER throughout the study period, including in situ (noninvasive cancer), 
local (invasive cancer confined to the breast), regional (tumor extension to breast skin, chest wall, 
and/or regional lymph nodes), and distant (metastasis to non-breast tissues). ER/PR status was 
recorded as positive, borderline, negative, and unknown. Given that clinical standards defining 
hormone receptor positivity changed over the study period, varying from 1-10%, we combined 
positive and borderline cases to approximate more recent guidelines of 1% positivity recommended 
by the American Society of Clinical Oncology/College of American Pathologists(90). Tumor grade 
was defined at time of diagnosis by a pathologist as low (well-differentiated), moderate (moderately-
differentiated), high (poorly-differentiated) and undifferentiated (anaplastic). Undifferentiated tumors 
(defined as grade 4) were uncommon (approximately 3% of cases) and were excluded from all grade 
analyses. Primary tumor size was defined as the single largest tumor dimension prior to any 
neoadjuvant cancer therapy and dichotomized as ≤2cm vs. >2cm.  
 We used SEER-Medicare linked data and defined diagnostic imaging technology use as at 
least one claim in a given calendar year for an imaging technology used to diagnose breast cancer 
metastases at the time of diagnosis, including CT, PET, MRI, and bone scans. Use of these 
technologies was defined using relevant Healthcare Common Procedure Coding System (HCPCS) 
and Current Procedural Terminology (CPT) imaging codes corresponding to these technologies from 
1992-2011 (Table 5.5). Breast cancer cases were considered “imaged” if at least one of these four 
imaging scans was received between 2 months prior and 4 months following the primary diagnosis 
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date within SEER. This exposure window was selected to identify imaging used incidentally prior to 
cancer diagnosis and to allow sufficient time for complete disease staging post-diagnosis(68, 98). 
5.2.3 Statistical analysis 
 To examine trends in distant breast cancer among young women <40 years of age during our 
20-year study period, we used SEER*Stat software (version 8.3.2(99)) to calculate annual stage-
specific breast cancer incidence rates from 1992-2011 in the SEER 13 program, adjusted for age 
using the 2000 U.S. standard population. Incidence rates were calculated for young women overall 
and stratified by black and white race to identify whether temporal trends in stage at diagnosis vary 
according to race. Joinpoint regression(72) (version 4.4.0.0(100)) was used to quantitatively assess 
temporal trends by fitting up to three joinpoints at statistically significant points at which the slope of 
the incidence trends changed. Annual percent change (APC) estimates were generated for each trend 
segment, and weighted average APCs (AAPCs) were calculated to generate a single percent estimate 
for 1992-2011 and to quantitatively compare trends across analyses(101). 
 To examine the “biological shift” hypothesis, we calculated annual stage-specific incidence 
rates and annual incidence rates according to ER/PR status, tumor grade, and primary tumor size, 
overall and among cases with distant stage disease at diagnosis. All incidence rates were adjusted for 
age using the 2000 U.S. standard population, and analyses of tumor characteristics were restricted to 
invasive breast cancer cases (N=26,870). We then used joinpoint regression to calculate AAPCs 
estimating temporal trends in stage and breast tumor characteristics from 1992-2011 among young 
women overall and according to race (black vs. white). Substantial missing data has been documented 
for tumor characteristics reported to SEER, particularly for ER and PR status (approximately 25% in 
1992), which may bias longitudinal studies of incidence rates(102, 103). To clarify whether data are 
missing at random across characteristics, we characterized patients with missing data by estimating 
descriptive statistics with chi-square significance testing for cases with and without missing data, and 
used joinpoint regression to examine whether the distribution of breast cancer cases (as measured by 
percent of cases) varied over time with respect to each tumor characteristic. 
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 To investigate the “stage migration” hypothesis, annual rates of imaging use were calculated 
overall and by imaging type (CT, PET, MRI, and bone scans) among older breast cancer cases in 
SEER-Medicare from 1992-2011. Joinpoint regression was used to estimate AAPCs for all 
longitudinal trends. Sensitivity analyses were conducted excluding elderly women (over age 75) as 
well as varying the 6-month imaging window to 3 months post-diagnosis; however, these exclusions 
did not substantially impact results beyond reductions in study power and therefore were not 
employed in final analyses (results not shown). Unconditional logistic regression was used to estimate 
age-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) to assess the associations between 
imaging use and tumor biological characteristics. Logistic regression analyses were performed using 
SAS software, version 9.4 (SAS Institute, Inc., Cary, North Carolina). Statistical significance for all 
analyses was defined at an α-level of 0.05.  
5.3 Results 
5.3.1 Incidence of distant and unstaged breast cancer among young women 
 In the SEER 13 registries, young (<40 years) breast cancer cases diagnosed from 1992-2011 
tended to have local or regional stage at diagnosis (11.6% in situ, 42.7% local, 37.6% regional, 6.1% 
distant, and 2.0% unstaged). Over the 20-year study period, joinpoint regression models revealed little 
change in the rates of in situ, local, and regional stage breast cancer (Figure 5.1). However, distant 
disease incidence significantly increased by an average of 3.2% annually while the rate of unstaged 
disease decreased dramatically by 6.8% per year. Comparing trends by race revealed that incidence of 
in situ disease increased for black but not white women (p=0.03; black AAPC=3.0%, 95% CI=0.5, 
5.7; white AAPC=0.7, 95% CI=-0.0, 1.5) while regional stage disease showed a significant increase 
for white but not black women over time (p=0.005; white AAPC=1.1, 95% CI=0.6, 1.5; black 
AAPC=-0.4, 95% CI=-1.1, 0.3). Distant stage breast cancer increased similarly across race (p=0.5; 
black AAPC=3.8, 95% CI=2.0, 5.5; white AAPC=3.4, 95% CI=2.5, 4.2) while unstaged disease 
showed marked declines over time for both races (p=0.4; black AAPC=-8.1, 95% CI=-10.7, -5.5; 
white AAPC=-5.8, 95% CI=-8.5, -3.1). Local disease incidence did not change significantly 
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according to race (p=0.06; black AAPC=-0.3, 95% CI=-1.1, 0.4; white AAPC=0.1, 95% CI=-0.3, 
0.4). 
5.3.2 Temporal incidence trends suggest increasing frequency of favorable tumor biological 
characteristics  
 To evaluate the “biological shift” hypothesis, we examined temporal trends in breast cancer 
incidence according to tumor characteristics and found that breast cancers among young women 
shifted toward more favorable prognostic features over time (Table 1). Rates of ER and PR positive 
disease increased significantly by 3.2% and 2.5% per year, respectively, while the incidence of 
negative hormone receptor status showed a significant decrease (ER status) or small increase (PR 
status) over time. Similarly, the rate of low grade tumors strongly increased over the study period 
compared to attenuated positive trends for moderate and high grade disease. Only tumor size showed 
a shift to less favorable disease features, with incidence of larger tumors >2cm significantly 
increasing over time by 1.7% per year and no change in smaller tumors. However, ascertainment of 
all tumor characteristics dramatically improved from 1992-2011, as the rate of missing data for each 
characteristic decreased with AAPCs of considerably higher magnitude than any of the changes in 
nonmissing disease categories. Unknown ER and PR status showed the strongest declines, with 
AAPCs of over 10% over the study period, while rates of unknown grade and tumor size status also 
decreased substantially by an average of 8.7% and 4.2% per year, respectively. Stratification by race 
did not reveal differences in incidence trends between white and black women for any of the tumor 
characteristics, except tumor size which showed a slight but significantly stronger increase in the rate 
of larger tumors for white compared to black women (p=0.05; white AAPC=1.9, 95% CI=1.5, 2.4; 
black AAPC=1.1, 95% CI=0.3, 1.8) (results not shown). 
 We investigated whether observed incidence trends for tumor characteristics differed when 
restricting to young women with distant disease. As shown in Table 1, strong increases in the 
incidence rates of both favorable and poor prognostic tumor features were evident for ER and PR 
status as well as grade, though the rates of positive change for favorable characteristics (ER positive, 
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PR positive, and low/moderate grade) were substantially larger than for less favorable features. 
However, the rates of unknown tumor characteristics showed significant declines for all three factors, 
particularly for ER and PR status which showed negative AAPCs of 9.5% and 11.2%, respectively, 
while unknown grade declined at a more modest but significant rate of 2.6% per year. In contrast, 
patterns for tumor size among young women with distant disease showed no temporal changes for 
smaller tumors ≤2cm or unknown tumor status, although larger tumors >2cm significantly increased 
by an average of 3.3% annually. 
5.3.3 Missing data contribute to biased incidence trends among young women 
The dramatic declines in the rates of missing data over time for stage at diagnosis and all 
tumor characteristics prompted an investigation into the level of potential bias that missing data 
contributes to observed temporal incidence trends. Women with unstaged breast cancer tended to be 
black race (p=0.01) and very slightly younger (p<0.0001) than women who were staged at diagnosis 
(Table 2). Additionally, unstaged women were significantly more likely to have larger tumors 
(p=0.004) with slightly increased ER positive disease (p=0.08), and were also highly likely to have 
missing data for other tumor characteristics as well (p<0.0001). However, we examined factors 
associated with unstaged disease in the earliest (1992-1996) and latest (2007-2011) five years of our 
study period to assess differences in missingness across time, and found that race was the only factor 
that significantly differed by stage status for the earliest cases (p=0.003). In contrast, the most recent 
unstaged cases were more likely to differ based on disease characteristics, including increased ER 
negative (p=0.003) and low grade disease (p=0.02). With regard to other tumor characteristics, mean 
age and race were not associated with unknown status for any factors other than tumor size, for which 
black women were significantly more likely to have missing data (p=0.04; results not shown).  
 To evaluate how improving ascertainment of tumor characteristics over time impacted 
temporal incidence trends, we excluded cases with missing data and examined the frequency 
distribution of young breast cancer cases over time with respect to each tumor characteristic. We 
found that the percent of breast cancer cases with more favorable tumor characteristics (specifically 
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ER/PR positive and low grade disease) increased significantly from 1992-2011, while the percent of 
cases with less favorable characteristics (ER/PR negative and high grade disease) decreased 
significantly over time (Table 3). Only tumor size showed an increase in less favorable disease over 
the study period, in that the percent of cases with larger tumor size >2cm showed a small but 
significant increase in frequency of 0.9% per year while smaller tumors declined significantly by 
1.4% per year. Comparing temporal trends in the incidence rate (Table 1) and frequency (Table 3) 
showed that temporal trends were more pronounced when evaluating rates, and were attenuated or 
even reversed when considering frequencies. 
These analyses were conducted among all women, so we also examined changes among 
women with distant disease (Table 3). We observed a significant decrease in the percent of cases with 
ER negative and high grade disease while the percent of cases with ER positive and low/moderate 
disease significantly increased. PR positive status appeared to increase, though not significantly. The 
distribution of small and larger tumor sizes did not significantly change over the study period. Figure 
5.2 illustrates incidence rates (panel A) and the distribution of ER status (panel B) among cases with 
distant disease over time, showing equivalence at approximately 50% for both ER positive and 
negative disease until 2001 when ER negative disease began to decrease, coinciding with lower rates 
of cases with unknown ER status. In comparison with Figure 5.2A, ER negative breast cancer showed 
slightly increasing rates over time that reversed to declines when frequency was assessed (Figure 
5.2B). 
5.3.4 Imaging technology use significantly increased over time and in association with tumor 
characteristics 
 Evaluating the “stage migration” hypothesis revealed strongly increased use of imaging 
technology from 1992-2011 in SEER-Medicare (Figure 5.3). The percent of Medicare women 
receiving any imaging within 2 months prior and 4 months following their breast cancer diagnosis 
significantly increased by an average of 1.4% (95% CI=0.5, 2.2) per year over the study period, with 
the strongest increases occurring after 1998. After stratifying by imaging type, the use of PET and 
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MRI scans dramatically increased over time, with the percent of cases receiving those imaging 
technologies increasing by 72.5% (95% CI=56.9, 88.6) and 13.7% (95% CI=11.1, 16.3) per year, 
respectively. The use of CT scans also significantly increased during this time period, though more 
gradually at 2.9% (95% CI=2.3, 3.6) per year. In contrast, the use of bone scans significantly 
decreased from 1992-2011 at a rate of 4.9% (95% CI=-5.9, -3.8) per year. 
 Logistic regression analyses revealed significant associations between imaging use and all 
tumor characteristics, with less favorable tumor characteristics being associated with increased 
imaging use (Table 4). A diagnosis of distant stage disease was most strongly associated with 
imaging use, with distant stage cases being 14.8 times more likely to receive imaging than women 
with local disease. Imaged cases were also more likely to have ER and PR negative disease as well as 
high grade and larger tumors. Additionally, imaged cases were less likely to have missing data for 
stage at diagnosis and all tumor characteristics. 
5.4 Discussion 
 From 1992-2011 in the SEER 13 registries, the incidence of distant stage breast cancer 
increased by 3.2% per year among young women <40 years, consistent with another recent report(4). 
Over this time period, we observed a shift to more favorable tumor characteristics and dramatic 
declines in the rates of missing data, suggesting that the rise in distant disease may not be attributable 
to increasing aggressive breast tumor biology. Additionally, investigating temporal diagnostic 
imaging patterns among older women ≥65 years revealed considerable increases in the use of PET, 
MRI, and CT scans over time, indicating that stage migration via imaging use may have contributed 
to shifting incidence trends. 
While initial analyses of temporal trends in tumor characteristics suggested significant 
increases in poor prognostic features among young women with distant disease (including ER and PR 
negativity, high grade, and larger tumor size >2cm), the substantial reductions in the rates of 
unknown disease status over time confound interpretation. Indeed, among young women with distant 
disease, the incidence of all nonmissing tumor categories increased over the study period, indicating 
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that longitudinal incidence rates were impacted by a redistribution of cases as ascertainment of 
missing tumor characteristics improved over time. We found that the distribution of young distant 
stage breast cancer cases with known tumor status trended toward more favorable characteristics over 
time, with the percent of cases having poor prognostic factors reversing the initial positive trend to 
show significant declines or no change over time for all characteristics. Others have reported similar 
patterns in the incidence of hormone receptor status, observing increased ER positive disease and 
decreased or stable ER negative disease for breast cancer cases of all ages, including young women 
<40 years(21, 64, 124). Johnson et al.(125) identified stronger increases in ER positive disease over 
time among young women with distant stage disease, but mixed results for ER negative disease in 
that ER-/PR+ disease significantly declined while ER-/PR- disease showed a small but significant 
increase over time. Studies investigating temporal trends in tumor grade and size have been less 
common, with one study identifying rising incidence rates for both low and high grade tumors among 
young women with a correspondingly large decrease in missing data(21). Others observed increasing 
incidence of smaller but not larger tumors among women over age 40 years(121), contrasting with 
our findings among young women. Taken together, these results provide little evidence for the 
biological shift hypothesis, suggesting that temporal trends in aggressive breast tumor characteristics 
do not explain the recent rise in distant breast cancer. 
Several studies evaluating incidence trends of breast tumor characteristics have used 
imputation methods(64, 102, 103, 124-126) to address any bias induced by the substantial changes in 
missing data over time. These authors have demonstrated that approximately 78% of breast cancer 
cases with missing data were identified as ER positive after imputation, and imputed incidence trends 
revealed marked declines in the rate of ER negative compared to ER positive disease that were not 
previously observed in with non-imputed data(102, 103). Our findings support these conclusions, as 
the distribution of ER status over time has trended toward ER positivity, and underscore the need for 
careful interpretation of trends in longitudinal studies of breast cancer incidence. 
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 We observed dramatic shifts in the use of imaging technologies over time among in SEER-
Medicare, with the strongest increases occurring for PET and MRI scans. Only bone scans showed a 
decrease in use from 1992-2011, particularly after 2001 as the rates of other imaging technologies 
increased. These trends coincide with increased Medicare coverage of PET and advanced imaging for 
breast cancer staging and highlight the shift to PET, MRI, and CT technologies, rather than bone 
scans, as the standard of care for identifying advanced stage cancers given improved sensitivity for 
diagnosing distant metastases(127-129). Increased use of PET imaging has been shown to cause stage 
migration and inflated distant disease trends in studies of lung cancer incidence patterns(66-69), 
though limited availability of large administrative healthcare databases linked to cancer populations 
has hampered evaluating patterns in younger breast cancer populations. Another recent study 
conducted within SEER-Medicare observed increased imaging among women with early stage breast 
cancer, but did not consider imaging in relation to distant stage disease(130). Other studies have 
found mixed evidence of stage migration in breast cancer incidence trends among young women, 
using quantitative comparisons of stage-specific incidence rate trends to assess whether stage shifts 
have occurred between regional and distant disease over time(4, 122). Evaluating whether survival 
has improved over time for cases presenting with distant and regional stage disease may clarify the 
impact of stage migration on the burden of advanced stage breast cancer among young women. 
We identified significant associations between imaging use and distant stage as well as 
aggressive tumor characteristics, suggesting that clinical recommendations for diagnostic imaging 
technology are strongly related to disease characteristics at diagnosis. Given that young women <40 
have a higher frequency of aggressive breast cancers, it is possible that these associations would be 
stronger in a younger population and prompt greater use of imaging in this demographic. Two recent 
studies reported that rates of imaging technology use at the time of breast cancer diagnosis were 
highest among young women(95, 131), with one estimating that imaging use among young women 
<40 years of age was approximately double the rate among elderly women eligible for Medicare 
(21% vs. 10%, respectively)(95). These results suggest that our estimates of imaging technology use 
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among SEER-Medicare cases are likely attenuated compared to those among younger women, and 
thus our findings may have underestimated the role of imaging use in shaping stage-specific 
incidence trends among young women over time.  
Our results should be considered in light of some limitations. While we sought to clarify the 
possible impacts of missing data on stage-specific trends and evaluate factors associated with 
missingness over time, our assessment of missing data was indirect and there may be an unknown 
pattern of bias. Additionally, our assessment of imaging use in our SEER-Medicare population may 
have included imaging that was received for reasons unrelated to breast cancer staging, and it is 
possible that some imaging data were missing from the Medicare claims. However, expensive 
healthcare services such as the imaging technologies we evaluated are likely to be well-represented in 
healthcare utilization data sources, and the lengthy staging process for many cases necessitates an 
imaging assessment period of at least several months(57, 96, 97). Finally, because we used imaging 
data from older women, we were unable to directly assess the extent of imaging use in the SEER 
population of young women <40 years, and we cannot directly determine whether stage migration via 
imaging use has impacted the rise in distant breast cancer in the SEER 13 program. While our use of 
SEER-Medicare data enabled the identification of imaging patterns in a national population of breast 
cancer cases, additional linkages of administrative healthcare databases to longitudinal cancer 
populations with representation of younger women are needed to assess the role of imaging on stage 
migration in incidence trends among young women. 
5.5 Conclusion 
 In summary, we found little evidence to suggest that breast cancers among young women <40 
years have become more aggressive from 1992-2011, and our findings do not support the hypothesis 
that shifting breast cancer biology has contributed to the rise in distant stage disease among young 
U.S. women. Shifting patterns in missing data within SEER have likely biased incidence trends 
according to stage and tumor characteristics, necessitating caution when interpreting potential causes 
and impacts of breast cancer incidence trends. Our findings suggest that stage migration via increased 
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diagnostic imaging use may have contributed to rising rates of distant breast cancer among young 
women. 
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Table 5.1. Average annual percent change (AAPC) estimates and 95% CIs for incidence of breast 
tumor characteristics among young women <40 years overall and with distant stage at diagnosis, 
1992-2011. 
 
 All stages  Distant 
ER status     
Positive 3.2 (2.8, 3.7)  8.2 (7.0, 9.4) 
Negative -0.9 (-1.8, -0.1)  3.8 (2.3, 5.2) 
Unknown -10.6 (-12.0, -9.1)  -9.5 (-12.0, -6.9) 
PR status    
Positive 2.5 (2.0, 3.0)  7.5 (6.0, 9.1) 
Negative 1.1 (0.3, 1.9)  5.4 (3.8, 7.1) 
Unknown -10.6 (-11.9, -9.3)  -11.2 (-15.0, -7.1) 
Grade    
Low 4.2 (2.9, 5.6)  9.5 (7.5, 11.5)a 
Moderate 2.1 (1.8, 2.5)   
High 1.5 (0.7, 2.3)  3.7 (2.9, 4.4) 
Unknown -8.5 (-10.1, -6.9)  -2.6 (-4.6, -0.5) 
Tumor size    
≤2 cm -0.3 (-1.2, 0.6)  1.5 (-4.2, 7.5) 
>2 cm 1.7 (1.3, 2.1)  3.3 (2.4, 4.1) 
Unknown -4.3 (-5.1, -3.4)  1.5 (-0.2, 3.3) 
acombined low/moderate grade due to small sample size. 
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Table 5.2. Descriptive statistics for young women <40 years with unstaged disease, overall and for early and more recent diagnosis years, 
SEER 13 program, 1992-2011. 
 All years  1992-1996  2007-2011 
 Staged Unstaged Χ2 p-value  Staged Unstaged Χ2 p-value  Staged Unstaged Χ2 p-value 
Mean age (SE) 35.1 (0.02) 34.1 (0.18) <0.0001a         
Race            
White 21,298 (72.0) 409 (70.6) 0.01  5,387 (74.5) 159 (67.7) 0.003  5,049 (69.3) 54 (70.1) 0.6 
Black 4,221 (14.3) 105 (18.1)   1,029 (14.2) 52 (22.1)   1,041 (14.3) 13 (16.9)  
Other 4,072 (13.8) 65 (11.2)   818 (11.3) 24 (10.2)   1,198 (16.4) b  
Unknown 202 35   45 16   78 b  
ER status            
Positive 14,443 (62.5) 101 (70.0) 0.08  2,936 (56.8) 28 (60.9) 0.6  4,366 (69.5) b 0.003 
Negative 8,661 (37.5) 44 (30.3)   2,234 (43.2) 18 (39.1)   1,913 (30.5) 30 (90.9)  
Unknown 3,152 469   1,308 205   213 52  
PR status            
Positive 12,945 (56.7) 85 (60.3) 0.4  2,818 (55.8) 24 (55.8) 1.0  3,758 (60.0) 22 (68.7) 0.3 
Negative 9,878 (43.3) 56 (39.7)   2,235 (44.2) 19 (44.2)   2,503 (40.0) b  
Unknown 3,433 473   1,425 208   231 53  
Grade            
Low 1,698 (7.4) 19 (8.7) 0.5  297 (6.0) b 0.1  516 (8.4) b 0.02 
Moderate 7,573 (32.8) 64 (29.4)   1,643 (33.0) 18 (22.5)   2,136 (34.9) 13 (38.2)  
High 13,814 (59.8) 135 (61.9)   3,036 (61.0) 57 (71.3)   3,465 (56.6) 14 (41.2)  
Unknown 2,439 385   1,217 164   309 50  
Tumor size            
≤2 cm 11,307 (45.9) 44 (33.3) 0.004  2,875 (48.3) 23 (39.7) 0.2  2,535 (41.1) b 0.4 
>2 cm 13,333 (54.1) 88 (66.7)   3,078 (51.7) 35 (60.3)   3,637 (58.9) 11 (68.8)  
Unknown 1,436 481   485 192   280 69  
ap-value obtained from linear regression analysis. 
b. Cell sizes <11 persons were suppressed to maintain confidentiality. 
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Table 5.3. Average annual percent change (AAPC) estimates and 95% CIs for the distribution of 
breast tumor characteristics among young women <40 years, overall and with distant stage at 
diagnosis, 1992-2011. 
 
 All stages  Distant 
ER status     
Positive 1.5 (1.1, 1.9)  1.9 (1.0, 2.7) 
Negative -2.7 (-3.4, -1.9)  -2.2 (-3.8, -0.6) 
PR status    
Positive 0.5 (0.1, 1.0)  1.1 (-0.3, 2.5) 
Negative -0.7 (-1.3, -0.1)  -1.0 (-2.2, 0.2) 
Grade    
Low 2.5 (1.4, 3.6)  4.4 (2.7, 6.0)a 
Moderate 0.4 (-0.3, 1.1)   
High -0.5 (-0.7, -0.3)  -1.1 (-1.7, -0.5) 
Tumor size    
≤2 cm -1.4 (-2.1, -0.7)  -1.2 (-3.7, 1.4) 
>2cm 0.9 (0.4, 1.4)  0.2 (-0.7, 1.2) 
acombined low/moderate grade due to small sample size. 
All cases with missing data for a given characteristic are excluded. 
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Table 5.4. Tumor characteristics associated with imaging technology use among women ≥65 years of 
age, SEER-Medicare 13 program, 1992-2011. 
 
Not imaged 
(N=34,872) 
Imaged 
(N=30,585) OR (95% CI)a 
Stage at diagnosis      
In situ 6,929 (20.3) 2,597 (8.6) 0.49 (0.47, 0.52 
Localized 22,065 (64.6) 15,833 (52.6) 1.0 
Regional 4,965 (14.5) 9,483 (31.5) 2.70 (2.59, 2.81) 
Distant 212 (0.6) 2,171 (7.2) 14.8 (12.9, 17.1) 
Unstaged 701 501  
ER status      
Positive (ref) 22,067 (85.7) 20,978 (81.9) 1.0 
Negative 3,694 (14.3) 4,628 (18.1) 1.30 (1.24, 1.37) 
Unknown 9,111 4,979  
PR status    
Positive (ref) 18,519 (53.1) 7,863 (31.1) 1.0 
Negative 6,762 (19.4) 17,384 (68.9) 1.24 (1.20, 1.29) 
Unknown 9,591 5,338  
Grade    
Low (ref) 7,013 (25.0) 5,281 (20.3) 1.0 
Moderate 12,787 (45.6) 11,414 (43.8) 1.19 (1.14, 1.25) 
High 8,245 (29.4) 9,377 (36.0) 1.52 (1.45, 1.59) 
Unknown 6,827 4,513  
Tumor size    
≤2 cm (ref) 22,963 (73.7) 16,281 (58.4) 1.0 
>2 cm 8,213 (26.3) 11,587 (41.6) 2.12 (2.05, 2.20) 
Unknown 3,696 2,717  
aadjusted for age at diagnosis.
 74 
 
Table 5.5. Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding 
System (HCPCS) codes defining diagnostic imaging technology use. 
Imaging Technology Category CPT/HCPCS Codes 
CT Brain/Head 70450-70492 
 Breast/Chest 72125-72133 
 Abdomen 71250-71270, 72192-72194, 74150-74170, 74176-74178 
 Bone 73200-73202, 73700-73702 
 Body 76380, 76497 
   
PET Body 
78608, 78609, 78810-78816, G0125, G0126, G0165, G0210-
G0228, G0231-G0235, G0252-G0254, G0296, G0330, G0331 
   
MRI Brain/Head 70336, 70540, 70542, 70543, 70551-70553, 70557-70559 
 Breast/Chest 
71550-71552, 75552, 75553, 75557, 75561, 76093, 76094, 
77058, 77059, C8903-C8908 
 Abdomen 72195-72197, 74181-74183 
 Bone 
72141, 72142, 72146-72149, 72156-72158, 73218-73223, 
73718-73723 
 Body 76498 
   
Bone scan  
(nuclear medicine) 
Bone/Body 
76400, 78800-78804, 78102-78104, 78300-78320, 78399, 
78999 
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Figure 5.1. Breast cancer incidence among women <40 years by SEER historic stage, SEER 13 
program, 1992-2011. 
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Figure 5.2. Distant breast cancer incidence among women <40 years according to ER status, SEER 13 program, 1992-2011. 
A. B. 
 
Figure 5.2 legend. Panels A and B show smoothed incidence rate trends estimated by joinpoint regression models. Panel B excludes cases with 
missing ER status.
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Figure 5.3. Diagnostic imaging use among older breast cancer patients ≥65 years in the SEER-
Medicare 13 program, 1992-2011. 
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CHAPTER 6: DISCUSSION 
6.1 Summary of findings 
 The aims of this dissertation were (1) to examine the biology and epidemiology of breast 
cancers among premenopausal young (<40 years) black women and (2) to evaluate whether shifts in 
breast cancer biology and/or stage migration due to increased imaging use have contributed to the rise 
in distant stage breast cancer among young women in the U.S. First, using data from the AMBER 
Consortium, one of the largest studies of breast cancer epidemiology among black women to date, we 
found that young-onset breast cancers showed more aggressive tumor characteristic patterns than 
older-onset tumors. Specifically, young women tended to have increased ER and PR negativity, 
triple-negative subtype, higher grade, larger tumor size, and more advanced stage at diagnosis than 
older women, suggesting that young-onset breast cancers have a distinct, poorer-prognostic biology 
compared to older-onset disease. Additionally, we observed evidence of distinct breast cancer 
etiology according to age at diagnosis, with young women showing stronger risk associations with 
family history of breast cancer and waist-to-hip ratio as well as a protective association for 
breastfeeding compared to older women. These etiologic patterns were strongest when assessing age 
differences using the youngest cutpoint (<40 years) compared to older cutpoints of 45 and 50 years of 
age, highlighting that etiologic differences appear to be most pronounced when comparing the 
youngest women to older women. Increasing breastfeeding and reducing abdominal adiposity and 
oral contraceptive use were identified as potentially modifiable targets for intervention against young-
onset disease among premenopausal black women. 
 Second, we used SEER and SEER-Medicare linked data to examine trends in young-onset 
breast cancer incidence, tumor biological characteristics, and diagnostic imaging use from 1992-2011. 
Among women <40 years of age, distant stage breast cancer incidence rates increased over time while 
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the rate of unstaged breast cancers markedly declined. Ascertainment of breast tumor characteristics 
also dramatically improved over time, with significant decreases in the rates of missing data for all 
tumor characteristics. We found evidence of a shift to more favorable breast tumor characteristics 
among young women since 1992, with the percent of cases with ER and PR negative as well as low 
grade disease increasing significantly over time while ER/PR negative and high grade disease 
significantly decreased. These trends were strongest when restricting to young women with distant 
stage disease, suggesting that the “biological shift” hypothesis has not contributed to rising distant 
breast cancer incidence rates. However, we observed significantly increased use of diagnostic 
imaging from 1992-2011, particularly PET and MRI scans, among Medicare-eligible SEER breast 
cancer cases, and imaging use was significantly associated with distant stage at diagnosis as well as 
poorer-prognostic tumor characteristics. Our work suggests that stage migration via increased 
imaging use may have contributed to rising rates of distant stage breast cancer among young women. 
6.2 The roles of biology, etiology, and technology in young women’s breast cancer 
 Among young, premenopausal black women <40 years, breast tumor biology showed a clear 
pattern of more aggressive disease characteristics compared to older-onset disease. This finding is 
consistent with other population-based studies of young women’s breast cancer(8, 21-23, 27, 48-53, 
57, 88, 105), supporting the hypothesis that breast cancers among young women <40 years are 
biologically distinct from those among older women. Interestingly, our evaluation of temporal trends 
in breast tumor characteristics in the SEER program did not reveal any evidence of increasing 
aggressive breast cancer biology from 1992-2011, but rather showed that young women’s breast 
cancer may be shifting toward more favorable disease features that are more common among older 
women. This result is counter to our “biological shift” hypothesis, and suggests that, while young 
women appear to have distinct and aggressive tumor biology patterns compared to older women, 
young-onset disease in the U.S. may be changing in a positive direction over time.  
 It is possible that the temporal shift to more favorable tumor biological characteristics among 
young women may be explained in part by changing patterns of breast cancer risk factor exposure. In 
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the first aim of this dissertation, we showed evidence of different breast cancer etiologic patterns 
according to age at diagnosis, particularly for body size and reproductive exposures. It is well-
established that rates of obesity have increased over the past several decades in the U.S.(132-134), 
and work conducted using the National Health and Nutrition Examination Survey (NHANES) has 
identified increasing rates of breastfeeding from 1993 to 2006, particularly among black women(135). 
We observed that these risk factors were associated with young women’s breast cancer in contrasting 
ways, with adiposity increasing the odds of young-onset disease and breastfeeding having a protective 
effect. Others have also shown that these factors are differentially associated with aggressive breast 
cancer subtypes, in that obesity increases risk of basal-like subtype among young women while 
breastfeeding may be protective(17-19). Given that we did not observe an increase in aggressive 
disease characteristics among women with distant breast cancer, it is unlikely that changing risk 
factor patterns are responsible for increasing rates of distant disease at diagnosis. However, temporal 
shifts in exposures such as adiposity and breastfeeding may be contributing to an increase in more 
favorable disease characteristics over our study period, highlighting their potential as intervention 
factors to reduce the burden of young women’s breast cancer in the U.S. 
 We identified that the changing use of diagnostic imaging technologies represents the most 
plausible explanation for the increasing trend in distant breast cancer incidence rates among young 
women. The dramatic increase in the percent of breast cancer cases receiving imaging use from 1992-
2011 and the strong association between imaging and stage at diagnosis suggest that more women are 
receiving diagnostic imaging technologies in connection with their breast cancer diagnosis, 
particularly those with advanced stage disease. While we were unable to directly assess imaging 
patterns among young women <40 years, other work has reported higher rates of diagnostic imaging 
among young compared to older women(95, 131). These usage patterns may be a response to the fact 
that young women <40 years tend to have more advanced stage at diagnosis, as young women are not 
recommended to receive regular mammographic screening and thereby rely on clinical and self-
detection methods(29, 31). Our work reveals that the rise in distant stage breast cancer among young 
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women may be a beneficial phenomenon, reflecting the use of improved and more accurate staging 
practices over time. Temporal changes in breast cancer incidence patterns may not be related to 
etiologic shifts requiring intervention, and cautious interpretation is warranted to prevent undue 
concern. 
6.3 Significance 
 This dissertation addressed two important gaps in epidemiologic research regarding young 
women’s breast cancer, characterizing the epidemiology of breast cancer among young black women 
and evaluating hypotheses for the rise in young-onset distant stage breast cancer in the U.S. Using the 
largest and most comprehensive data programs to date, the AMBER Consortium and the SEER and 
SEER-Medicare cancer registries, this research provides much-needed insight into the biology and 
etiology of young black women’s breast cancer and clarifies the public health impact of shifting 
breast cancer incidence trends among young women.  
 Our findings demonstrate that young black women are significantly more likely to have 
breast cancers with poorer-prognostic characteristics, underscoring the need for effective 
interventions to reduce the burden of breast cancer in this demographic. We identified a specific 
pattern of modifiable factors that could be targeted to decrease the risk of young-onset breast cancers 
among black women, including promoting breastfeeding and reducing both abdominal adiposity and 
the use of oral contraceptives. Additionally, these etiologic differences did not differ by ER status, 
suggesting that interventions targeting young women may protect against young-onset disease across 
tumor subtypes. This research represents one of the largest epidemiologic studies of breast cancer 
among young black women to date and provides key insight into the biologic and etiologic features 
that distinguish young-onset disease from that of older-onset breast cancers. 
  Additionally, this dissertation is the first investigation of two competing hypotheses for the 
observed rise in distant breast cancer incidence rates among young women from 1992-2011. By 
evaluating temporal trends in both breast cancer tumor characteristics and diagnostic imaging use, 
this research provided a comprehensive analysis of the most plausible contributors to shifting distant 
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disease incidence trends. Our work identifies that imaging use increased dramatically from 1992-2011 
while breast tumor characteristics showed correspondingly small incidence shifts to more favorable 
disease features, and stage migration due to improved imaging use should be considered as a key 
contributor to distant breast cancer incidence patterns among young women. This research 
underscores the importance of evaluating contrasting reasons for shifting temporal incidence trends 
and asserts that increasing rates of distant breast cancer among young women may be a beneficial 
result of more accurate staging practices over time.  
6.4 Future Directions 
 In this dissertation, we identified potentially modifiable risk factors associated with breast 
cancer among young black women. While large epidemiologic studies of breast cancer with sufficient 
representation of young and black women are rare, increased attention to this at-risk demographic 
would enable validation of our findings in other study populations. Only one known prospective 
cohort study to date, the Black Women’s Health Study(108), has evaluated risk factors associated 
with incidence of young-onset disease, and this study was included within the AMBER Consortium. 
Future prospective epidemiologic work in other study populations would improve understanding 
regarding the impact of these factors and associated interventions on the risk of young-onset breast 
cancer. 
We found little evidence that the biology of young-onset breast cancers changed over time 
within the SEER 13 program; however, we posited that temporal trends in risk factor exposure may 
have shifted over time in ways that influence breast cancer incidence patterns among young women. 
In our study, abdominal adiposity and oral contraceptive use were associated with increased odds of 
young-onset breast cancer, while breastfeeding was protective. Increasing rates of obesity, hormone 
use, and breastfeeding behaviors over time could impact patterns in breast tumorigenesis and 
progression, resulting in a temporal shift in breast cancer incidence. Furthermore, evidence suggests 
that these factors are differentially associated with breast tumor subtypes(17-19), thus potentially 
influencing trends in tumor biological features as well. Due to the nature of longitudinal studies and 
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the need for existing data extending back to the 1990s, epidemiologic studies of temporal patterns in 
etiologic factors have been rare. However, future studies examining demographic and risk factor data 
over time within the NHANES program and other longitudinal data programs may reveal connections 
between shifting etiologic factors and cancer incidence trends. 
Finally, our work identifies that stage migration resulting from increased imaging use may 
have contributed to shifting distant breast cancer incidence trends among young women. We 
evaluated this hypothesis by examining longitudinal trends in the use of four major diagnostic 
imaging technologies used for breast cancer staging (i.e., PET, MRI, CT, and bone scans) and found 
dramatic changes in imaging use since 1992. Under the stage migration hypothesis, the use of 
imaging would result in improved identification of distant metastases at time of diagnosis; therefore, 
young breast cancer cases receiving imaging would be accurately classified as having distant stage 
rather than regional stage at diagnosis. This reclassification of cases would increase the incidence of 
distant disease while improving disease prognosis due to the earlier identification of metastases. 
Future studies examining longitudinal trends in stage-specific breast cancer survival among young 
women would further clarify the role of stage migration, as survival would be expected to improve 
among both distant and regional stage cases over time. Additionally, evaluating whether stage-
specific incidence rates have changed among young women according to imaging status would enable 
a direct assessment of the association between imaging use and incidence trends in young-onset 
distant stage breast cancer. 
6.5 Conclusions 
 In conclusion, this dissertation examined the ways in which breast cancer biology and 
etiology differ according to age at diagnosis among black women and addressed possible underlying 
causes for the recent rise in distant breast cancer incidence among young women <40 years of age. 
We identified potentially modifiable targets for the prevention of breast cancers among young black 
women, a key demographic at risk for aggressive, advanced stage disease and higher mortality. 
Additionally, this work included a novel and thorough evaluation of the most credible contributors to 
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the rise in young-onset distant breast cancer from 1992-2011, considering the roles of shifting breast 
cancer biology and diagnostic imaging use patterns over time. We clarified the public health impact 
of observed incidence trends, identifying stage migration and sharply decreasing rates of missing data 
as key factors that may explain the rise in distant disease among young women. This work highlights 
the need for cautious interpretation of longitudinal cancer incidence patterns, as shifting trends may 
not be related to disease etiology. 
 
  
 
 
85 
 
REFERENCES 
 
1. Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 
2014;64:52-62. 
 
2. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, et al. Trends in breast cancer 
by race and ethnicity: update 2006. CA Cancer J Clin 2006;56:168-83. 
 
3. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer 
incidence. N Engl J Med 2012;367:1998-2005. 
 
4. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among 
women in the United States, 1976 to 2009. JAMA 2013;309:800-5. 
 
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular 
portraits of human breast tumours. Nature 2000;406:747-52. 
 
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression 
patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad 
Sci U S A 2001;98:10869-74. 
 
7. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression 
profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6. 
 
8. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast 
cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502. 
 
9. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer 
classification and prognosis based on gene expression profiles from a population-based study. Proc 
Natl Acad Sci U S A 2003;100:10393-8. 
 
10. Sandhu R, Parker JS, Jones WD, Livasy CA, Coleman WB. Microarray-Based Gene 
Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets 
for Therapy. Lab Med 2010;41:364-72. 
 
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: 
correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 
1987;235:177-82. 
 
12. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of 
HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer 
Study Group. J Clin Oncol 1993;11:1936-42. 
 
13. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic 
behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7. 
 
14. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the 
treatment of HER-2-positive early breast cancer. Oncologist 2006;11 Suppl 1:4-12. 
 
 
 
86 
 
15. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy 
and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic 
breast cancer. J Clin Oncol 2002;20:719-26. 
 
16. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with 
metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J 
Clin Oncol 2010;28:92-8. 
 
17. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. 
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39. 
 
18. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. 
Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer  
Epidemiol Biomarkers Prev 2004;13:1558-68. 
 
19. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. 
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast 
Cancer Association Consortium studies. J Natl Cancer Inst 2011;103:250-63. 
 
20. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 
2011;61:409-18. 
 
21. Anderson WF, Chen BE, Brinton LA, Devesa SS. Qualitative age interactions (or effect 
modification) suggest different cancer pathways for early-onset and late-onset breast cancers. Cancer 
Causes Control 2007;18:1187-98. 
 
22. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. 
Semin Oncol 2009;36:237-49. 
 
23. Keegan TH, DeRouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer  
subtypes in adolescent and young adult women. Breast Cancer Res 2012;14:R55. 
 
24. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, et al. Effects of 
young age at presentation on survival in breast cancer. BMC Cancer 2006;6:194. 
 
25. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in young 
women: clinicopathological features and biological specificity. Breast 2003;12:247-50. 
 
26. Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base report on breast 
carcinoma characteristics and outcome in relation to age. Cancer 1996;78:1838-43. 
 
27. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at 
diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns 
of gene expression. J Clin Oncol 2008;26:3324-30. 
 
28. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in 
young women: poor survival despite intensive treatment. PLoS One 2009;4:e7695. 
 
29. Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST. Stage 0 to stage III breast cancer in 
young women. J Am Coll Surg 2000;190:523-9. 
 
 
 
87 
 
30. Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer 
patients have worse outcomes? J Surg Res 2003;113:109-13. 
 
31. Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, et al. Breast cancer 
presentation and diagnostic delays in young women. Cancer 2014;120:20-5. 
 
32. Velentgas P, Daling JR. Risk factors for breast cancer in younger women. J Natl Cancer Inst 
Monogr 1994:15-24. 
 
33. Anderson WF, Matsuno RK, Sherman ME, Lissowska J, Gail MH, Brinton LA, et al. 
Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer 
Causes Control 2007;18:439-47. 
 
34. White E, Malone KE, Weiss NS, Daling JR. Breast cancer among young U.S. women in 
relation to oral contraceptive use. J Natl Cancer Inst 1994;86:505-14. 
 
35. Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Breast 
cancers among very young premenopausal women (United States). Cancer Causes Control 
2003;14:151-60. 
 
36. Warner ET, Colditz GA, Palmer JR, Partridge AH, Rosner BA, Tamimi RM. Reproductive 
factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and 
after age 40? Breast Cancer Res Treat 2013;142:165-75. 
 
37. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in 
the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer 
Res Treat 2005;90:127-37. 
 
38. Tavani A, Gallus S, La Vecchia C, Negri E, Montella M, Dal Maso L, et al. Risk factors for 
breast cancer in women under 40 years. Eur J Cancer 1999;35:1361-7. 
 
39. Hirose K, Tajima K, Hamajima N, Inoue M, Takezaki T, Kuroishi T, et al. A large-scale, 
hospital-based case-control study of risk factors of breast cancer according to menopausal status. Jpn 
J Cancer Res 1995;86:146-54. 
 
40. Newcomb PA, Storer BE, Longnecker MP, Mittendorf R, Greenberg ER, Clapp RW, et al. 
Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med 1994;330:81-7. 
 
41. Borges VF, Schedin PJ. Pregnancy-associated breast cancer: an entity needing refinement of 
the definition. Cancer 2012;118:3226-8. 
 
42. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. J 
Mammary Gland Biol Neoplasia 2009;14:87-98. 
 
43. Pathak DR, Speizer FE, Willett WC, Rosner B, Lipnick RJ. Parity and breast cancer risk: 
possible effect on age at diagnosis. Int J Cancer 1986;37:21-5. 
 
44. Hunter DJ, Willett WC. Diet, body size, and breast cancer. Epidemiol Rev 1993;15:110-32. 
 
45. Ursin G, Longnecker MP, Haile RW, Greenland S. A meta-analysis of body mass index and 
risk of premenopausal breast cancer. Epidemiology 1995;6:137-41. 
 
 
88 
 
 
46. Franceschi S, Favero A, La Vecchia C, Baron AE, Negri E, Dal Maso L, et al. Body size 
indices and breast cancer risk before and after menopause. Int J Cancer 1996;67:181-6. 
 
47. Brinton LA, Swanson CA. Height and weight at various ages and risk of breast cancer. Ann 
Epidemiol 1992;2:597-609. 
 
48. Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM. Age-related crossover in 
breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst 
2008;100:1804-14. 
 
49. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific 
incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 
2012;104:1094-101. 
 
50. Furberg H, Millikan R, Dressler L, Newman B, Geradts J. Tumor characteristics in African 
American and white women. Breast Cancer Res Treat 2001;68:33-43. 
 
51. Cunningham JE, Montero AJ, Garrett-Mayer E, Berkel HJ, Ely B. Racial differences in the 
incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor 
status. Cancer Causes Control 2010;21:399-409. 
 
52. Hahn KM, Bondy ML, Selvan M, Lund MJ, Liff JM, Flagg EW, et al. Factors associated with 
advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed 
breast cancer. Am J Epidemiol 2007;166:1035-44. 
 
53. Jones BA, Kasl SV, Curnen MG, Owens PH, Dubrow R. Can mammography screening 
explain the race difference in stage at diagnosis of breast cancer? Cancer 1995;75:2103-13. 
 
54. Lannin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS. Influence of 
socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. 
JAMA 1998;279:1801-7. 
 
55. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by 
race and ethnicity. Arch Intern Med 2003;163:49-56. 
 
56. Moorman PG, Jones BA, Millikan RC, Hall IJ, Newman B. Race, anthropometric factors, and 
stage at diagnosis of breast cancer. Am J Epidemiol 2001;153:284-91. 
 
57. Richardson JL, Langholz B, Bernstein L, Burciaga C, Danley K, Ross RK. Stage and delay in 
breast cancer diagnosis by race, socioeconomic status, age and year. Br J Cancer 1992;65:922-6. 
 
58. McGee SA, Durham DD, Tse CK, Millikan RC. Determinants of breast cancer treatment 
delay differ for African American and White women. Cancer Epidemiol Biomarkers Prev 
2013;22:1227-38. 
 
59. Hall IJ, Moorman PG, Millikan RC, Newman B. Comparative analysis of breast cancer risk 
factors among African-American women and White women. Am J Epidemiol 2005;161:40-51. 
 
60. Mayberry RM. Age-specific patterns of association between breast cancer and risk factors in 
black women, ages 20 to 39 and 40 to 54. Ann Epidemiol 1994;4:205-13. 
 
 
89 
 
 
61. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor 
characteristics among U.S. women. Breast Cancer Res 2007;9:R28. 
 
62. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among 
younger women in the United States. J Natl Cancer Inst 2008;100:1643-8. 
 
63. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer 
Statistics Review, 1975-2011: National Cancer Institute. Bethesda, MD; 2014. based on November 
2013 SEER data submission, posted to the SEER web site, April 4]. Available from: 
http://seer.cancer.gov/csr/1975_2011/. 
 
64. Hou N, Huo D. A trend analysis of breast cancer incidence rates in the United States from 
2000 to 2009 shows a recent increase. Breast Cancer Res Treat 2013;138:633-41. 
 
65. McDougall JA, Li CI. Trends in distant-stage breast, colorectal, and prostate cancer incidence  
rates from 1992 to 2004: potential influences of screening and hormonal factors. Horm Cancer 
2010;1:55-62. 
 
66. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new 
diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 
1985;312:1604-8. 
 
67. Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R. The effect of FDG-PET 
on the stage distribution of non-small cell lung cancer. J Thorac Oncol 2008;3:135-9. 
 
68. Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Jr., et al. Stage 
migration, selection bias, and survival associated with the adoption of positron emission tomography 
among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol 
2012;30:2725-30. 
 
69. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN, Jr. Positron emission 
tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon 
revisited. Arch Intern Med 2008;168:1541-9. 
 
70. Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The changing 
incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. 
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for 
Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18:1763-9. 
 
71. Glass AG, Lacey JV, Jr., Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: 
combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor 
status. J Natl Cancer Inst 2007;99:1152-61. 
 
72. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with 
applications to cancer rates. Stat Med 2000;19:335-51. 
 
73. Wo JY, Chen K, Neville BA, Lin NU, Punglia RS. Effect of very small tumor size on cancer-
specific mortality in node-positive breast cancer. J Clin Oncol 2011;29:2619-27. 
 
 
 
90 
 
74. Yu KD, Jiang YZ, Chen S, Cao ZG, Wu J, Shen ZZ, et al. Effect of large tumor size on 
cancer-specific mortality in node-negative breast cancer. Mayo Clin Proc 2012;87:1171-80. 
 
75. Yu KD, Wu J, Shen ZZ, Shao ZM. Hazard of breast cancer-specific mortality among women 
with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended 
endocrine therapy. J Clin Endocrinol Metab 2012;97:E2201-9. 
 
76. Palmer JR, Ambrosone CB, Olshan AF. A collaborative study of the etiology of breast cancer 
subtypes in African American women: the AMBER consortium. Cancer Causes Control 2014;25:309-
19. 
 
77. Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, et al. The Carolina 
Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast 
Cancer Res Treat 1995;35:51-60. 
 
78. Hair BY, Hayes S, Tse CK, Bell MB, Olshan AF. Racial differences in physical activity 
among breast cancer survivors: implications for breast cancer care. Cancer 2014;120:2174-82. 
 
79. Rosenberg L, Adams-Campbell L, Palmer JR. The Black Women's Health Study: a follow-up 
study for causes and preventions of illness. J Am Med Womens Assoc 1995;50:56-8. 
 
80. Rosenberg L, Palmer JR, Bethea TN, Ban Y, Kipping-Ruane K, Adams-Campbell LL. A 
prospective study of physical activity and breast cancer incidence in African-American women. 
Cancer Epidemiol Biomarkers Prev 2014;23:2522-31. 
 
81. Ambrosone CB, Zirpoli G, Ruszczyk M, Shankar J, Hong CC, McIlwain D, et al. Parity and 
breastfeeding among African-American women: differential effects on breast cancer risk by estrogen 
receptor status in the Women's Circle of Health Study. Cancer Causes Control 2014;25:259-65. 
 
82. National Cancer Institute. Surveillance, Epidemiology, and End Results Program  [January 
10, 2015]. Available from: seer.cancer.gov. 
 
83. Mohanty S, Bilimoria KY. Comparing national cancer registries: The national cancer data 
base (NCDB) and the surveillance, epidemiology, and end results (SEER) program. J Surg Oncol 
2014. 
 
84. Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, 
epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US 
elderly. Am J Epidemiol 2011;174:860-70. 
 
85. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare 
data: content, research applications, and generalizability to the United States elderly population. Med 
Care 2002;40:IV-3-18. 
 
86. National Cancer Institute: Applied Research, Cancer Control and Population Sciences. 
SEER-Medicare linked database. 
 
87. National Heart, Lung, and Blood Institute (NHLBI) Expert Panel on the identification, 
evaluation, and treatment of overweight and obesity in adults. Clinical Guidelines on the 
Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence 
Report. National Institutes of Health. Obes Res 1998;6 Suppl 2:51S-209S. 
 
 
91 
 
 
88. Chollet-Hinton L, Anders CK, Tse CK, Bell MB, Yang YC, Carey LA, et al. Breast cancer 
biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast 
Cancer Study: a case-control study. Breast Cancer Res 2016;18:79. 
 
89. Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, et al. Performance of Three-
Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium. 
Cancer Epidemiol Biomarkers Prev 2016;25:470-8. 
 
90. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American 
Society of Clinical Oncology/College Of American Pathologists guideline recommendations for 
immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 
2010;28:2784-95. 
 
91. Bernstein JR. Role of stereotactic breast biopsy. Semin Surg Oncol 1996;12:290-9. 
 
92. Yim JH, Barton P, Weber B, Radford D, Levy J, Monsees B, et al. Mammographically 
detected breast cancer. Benefits of stereotactic core versus wire localization biopsy. Ann Surg 
1996;223:688-97; discussion 97-700. 
 
93. Kaufman CS, Delbecq R, Jacobson L. Excising the reexcision: stereotactic core-needle 
biopsy decreases need for reexcision of breast cancer. World J Surg 1998;22:1023-7; discussion 8. 
 
94. Morrow M, Venta L, Stinson T, Bennett C. Prospective comparison of stereotactic core 
biopsy and surgical excision as diagnostic procedures for breast cancer patients. Ann Surg 
2001;233:537-41. 
 
95. Gold LS, Buist DS, Loggers ET, Etzioni R, Kessler L, Ramsey SD, et al. Advanced 
diagnostic breast cancer imaging: variation and patterns of care in washington state. J Oncol Pract 
2013;9:e194-202. 
 
96. Gorin SS, Heck JE, Cheng B, Smith SJ. Delays in breast cancer diagnosis and treatment by 
racial/ethnic group. Arch Intern Med 2006;166:2244-52. 
 
97. Gorey KM, Luginaah IN, Holowaty EJ, Fung KY, Hamm C. Wait times for surgical and 
adjuvant radiation treatment of breast cancer in Canada and the United States: greater socioeconomic 
inequity in America. Clin Invest Med 2009;32:E239-49. 
 
98. Dinan MA, Curtis LH, Hammill BG, Patz EF, Jr., Abernethy AP, Shea AM, et al. Changes in 
the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. 
JAMA 2010;303:1625-31. 
 
99. Surveillance Research Program, National Cancer Institute SEER*Stat software 
(seer.cancer.gov/seerstat) version 8.3.2. 
 
100. Joinpoint Regression Program, Version 4.4.0.0 - January 2017. Statistical Methodology and 
Applications Branch, Surveillance Research Program, National Cancer Institute. 
 
101. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent 
change in trend analysis. Stat Med 2009;28:3670-82. 
 
 
 
92 
 
102. Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the United States: 
current and future trends. J Natl Cancer Inst 2011;103:1397-402. 
 
103. Howlader N, Noone AM, Yu M, Cronin KA. Use of imputed population-based cancer 
registry data as a method of accounting for missing information: application to estrogen receptor 
status for breast cancer. Am J Epidemiol 2012;176:347-56. 
 
104. Gold LS, Klein G, Carr L, Kessler L, Sullivan SD. The emergence of diagnostic imaging 
technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical 
guidelines. Cancer Imaging 2012;12:13-24. 
 
105. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast 
cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 
1994;86:705-12. 
 
106. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity 
and lactation in relation to estrogen receptor negative breast cancer in African American women. 
Cancer Epidemiol Biomarkers Prev 2011;20:1883-91. 
 
107. Palmer JR, Viscidi E, Troester MA, Hong CC, Schedin P, Bethea TN, et al. Parity, lactation, 
and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl 
Cancer Inst 2014;106. 
 
108. Bertrand KA, Bethea TN, Adams-Campbell LL, Rosenberg L, Palmer JR. Differential 
patterns of risk factors for early-onset breast cancer by ER status in African American women. 
Cancer Epidemiol Biomarkers Prev 2016. 
 
109. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk 
of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among 
women 20-44 years of age. Breast Cancer Res Treat 2013;137:579-87. 
 
110. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, et al. A 
multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 
2000;151:346-57. 
 
111. Connolly BS, Barnett C, Vogt KN, Li T, Stone J, Boyd NF. A meta-analysis of published 
literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer 2002;44:127-38. 
 
112. Mannisto S, Pietinen P, Pyy M, Palmgren J, Eskelinen M, Uusitupa M. Body-size indicators 
and risk of breast cancer according to menopause and estrogen-receptor status. Int J Cancer 
1996;68:8-13. 
 
113. Huang Z, Willett WC, Colditz GA, Hunter DJ, Manson JE, Rosner B, et al. Waist 
circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol 
1999;150:1316-24. 
 
114. Li R, Darling N, Maurice E, Barker L, Grummer-Strawn LM. Breastfeeding rates in the 
United States by characteristics of the child, mother, or family: the 2002 National Immunization 
Survey. Pediatrics 2005;115:e31-7. 
 
 
 
93 
 
115. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk factors for 
triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 
2009;18:1157-66. 
 
116. Bethea TN, Rosenberg L, Hong CC, Troester MA, Lunetta KL, Bandera EV, et al. A case-
control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast 
Cancer Epidemiology and Risk Consortium. Breast Cancer Res 2015;17:22. 
 
117. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, et al. Oral 
contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995;87:827-35. 
 
118. Colditz GA, Kaphingst KA, Hankinson SE, Rosner B. Family history and risk of breast 
cancer: nurses' health study. Breast Cancer Res Treat 2012;133:1097-104. 
 
119. Collaborative Group on Hormonal Factors in Breast C. Familial breast cancer: collaborative 
reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast 
cancer and 101,986 women without the disease. Lancet 2001;358:1389-99. 
 
120. Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, et al. Biologic 
characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000;92:743-9. 
 
121. Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast 
carcinoma survival in the U.S.: 1975-1999. Cancer 2005;104:1149-57. 
 
122. Polednak AP. Increase in Distant Stage Breast Cancer Incidence Rates in US Women Aged 
25-49 Years, 2000-2011: The Stage Migration Hypothesis. J Cancer Epidemiol 2015;2015:710106. 
 
123. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) 
SEER*Stat Database: Incidence - SEER 13 Regs Research Data, Nov 2015 Sub (1992-2011) 
<Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1992-2011 
Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems 
Branch, released April 2016, based on the November 2015 submission. 
 
124. DeSantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in U.S. women 
are no longer declining. Cancer Epidemiol Biomarkers Prev 2011;20:733-9. 
 
125. Johnson RH, Chien FL, Bleyer A. Incidence rate of breast cancer in young women--reply. 
JAMA 2013;309:2435-6. 
 
126. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger PA. A multivariate technique 
for multiply imputing missing values using a sequence of regression models. Surv Methodol 
2001;27:85-95. 
 
127. McCartan DP, Prichard RS, MacDermott RJ, Rothwell J, Geraghty J, Evoy D, et al. Role of 
bone scan in addition to CT in patients with breast cancer selected for systemic staging. Br J Surg 
2016;103:839-44. 
 
128. Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, et al. FDG-PET/CT 
compared with conventional imaging in the detection of distant metastases of primary breast cancer. 
Oncologist 2011;16:1111-9. 
 
 
 
94 
 
129. Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, et al. 
Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, 
conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 
2008;19:1249-54. 
 
130. Crivello ML, Ruth K, Sigurdson ER, Egleston BL, Evers K, Wong YN, et al. Advanced 
imaging modalities in early stage breast cancer: preoperative use in the United States Medicare 
population. Ann Surg Oncol 2013;20:102-10. 
 
131. Stout NK, Nekhlyudov L, Li L, Malin ES, Ross-Degnan D, Buist DS, et al. Rapid increase in 
breast magnetic resonance imaging use: trends from 2000 to 2011. JAMA Intern Med 2014;174:114-
21. 
 
132. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, 
regional, and global trends in body-mass index since 1980: systematic analysis of health examination 
surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 
2011;377:557-67. 
 
133. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J 
Obes (Lond) 2013;37:889-91. 
 
134. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the 
distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7. 
 
135. McDowell MM, Wang CY, Kennedy-Stephenson J. Breastfeeding in the United States: 
findings from the national health and nutrition examination surveys, 1999-2006. NCHS Data Brief 
2008:1-8. 
 
